← 產業報告目錄

Nuclear Medicine Software Market by Software (Image Management, Workflow, PACS, Dosimetry, Treatment, AI/Analytics), Application (Diagnosis, Treatment, Theranostics, Research), Disease (Onco, Neuro, Cardio), End User & Region - Global Forecast to 2030

出版商 MarketsandMarkets產業別 Healthcare & Life Sciences出版日期 2025-07-23頁數 465報告編號 HIT9441

授權報價

Single User Licence$4,950 USD
Multi User Licence$6,650 USD
Corporate User Licence$8,150 USD
Global User Licence$10,000 USD
洽詢購買 申請 Sample

報告摘要

The nuclear medicine software market was valued at USD 970.03 million in 2025 and is estimated to reach USD 1,491.6 million by 2030, registering a CAGR of 9.0% during the forecast period. Growth in the nuclear medicine software market is being influenced by a convergence of clinical and technological advancements, along with favorable regulatory and reimbursement frameworks in developed and developing nations. These technological advancements are significantly transforming how nuclear medicine imaging and radiopharmaceutical therapies are delivered. Key factors driving growth include the increasing demand for accurate image analysis, PACS integration, dosimetry, treatment planning, advanced analytics, and reporting. In addition to the growing demand in the diagnostic imaging segment, nuclear medicine therapeutic applications are seeing an increase in the adoption rates of theranostics. Leading market players are increasingly integrating their solutions with AI-powered tools for tumor segmentation and automated reporting, thereby enhancing diagnostic accuracy and workflow efficiency. The pharmaceutical and life sciences sectors are fueling the demand for advanced nuclear medicine software solutions due to the expanding pipeline of radiopharmaceuticals. Furthermore, the growing transition towards cloud-native PACS integration and remotely accessible solutions is promoting the development of advanced software solutions. However, the growth of this market is moderately restrained due to challenges arising from data security, inadequate infrastructure, and radiation exposure. “Cloud-native platforms are expected to register the fastest growth over the forecast period.” The lucrative growth of cloud-native platforms is attributed to the increasing demand for remote access, interoperability, and scalability across healthcare systems. Nuclear medicine is rapidly evolving through multi-center collaborations and AI-powered analytics, driving the need for cloud-native solutions. These platforms enable real-time data sharing, faster software updates, and enhanced cybersecurity features. Furthermore, healthcare systems are transitioning towards a value-based care approach, in which cloud-developed infrastructure supports integrated decision-making, thereby enhancing overall patient care. Moreover, the adoption of advanced nuclear medicine workflows requires cloud-based software platforms that can synchronize imaging and treatment planning. Some companies offering cloud-native platforms include Sectra’s Cloud Imaging Platform and Intelerad’s IntelePACS Cloud. These solutions support PET/SPECT viewing and reporting, seamlessly integrating with AI modules for remote accessibility. “The subscription-based/Software-as-a-service (SaaS) models segment held the largest share of the nuclear medicine software market in 2024.” The subscription-based Software-as-a-Service (SaaS) model segment dominates the software licensing segment in the nuclear medicine software market in 2024. This dominance is due to the lower upfront costs, flexibility, and cloud-based deployments offered by this model. Healthcare providers, life sciences companies, and research institutes are increasingly shifting from traditional perpetual licensing models because of the high capital expenditures and limited scalability associated with them. SaaS models provide regular software updates with predictable operational costs and seamlessly integrate with cloud-native PACS and radiology systems, thereby supporting hospitals and imaging centers in modernizing their nuclear imaging workflows. With the expansion of multi-site imaging networks, SaaS platforms enable centralized data access, interoperable workflows, and remote access diagnostics. Some of the leading market players offering their solutions through subscription-based SaaS models are GE Healthcare and Siemens Healthineers. “North America market accounts for the largest share in the nuclear medicine software market in 2024.” The North American market dominated the nuclear medicine software sector in 2024, due to its advanced healthcare infrastructure, increasing adoption of hybrid imaging systems, and strong regulatory support for radiopharmaceutical-based diagnostics and therapeutics. Additionally, the significant presence of market leaders such as GE Healthcare and Siemens Healthineers contributes to the growth of the North American market. In contrast, the Asia Pacific market is expected to register the fastest growth rate over the forecast period. This growth is attributed to rising public and private investments in precision medicine, an escalating disease burden from cancer and cardiovascular diseases, and advancements in infrastructure across China, India, Japan, Australia, and South Korea. Furthermore, the region is experiencing rapid adoption of personalized dosimetry and theranostics, alongside increasing partnerships between local hospitals and globally established companies. Growing patient awareness, rising healthcare IT expenditure, and the increasing adoption of AI-based imaging solutions are further boosting growth in the Asia Pacific market. In-depth interviews have been conducted with chief executive officers (CEOs), Directors, and other executives from various key organizations operating in the nuclear medicine software marketplace. The breakdown of primary participants is as mentioned below: • By Company Type - Tier 1 (31%), Tier 2 (31%), and Tier 3 (28%) • By Designation - C-level Executives (44%), Director-level (31%), and Managers (25%) • By Region - North America (45%), Europe (28%), Asia Pacific (20%), Latin America (4%), and Middle East & Africa (3%) Key Players in the Nuclear Medicine Software Market Prominent players in the nuclear medicine software market include include GE HealthCare (MIM Software Inc.)(US), Siemens Healthineers AG(Germay), Koninklijke Philips N.V. (Netherlands), Lantheus Holdings, Inc. (EXINI Diagnostics AB)(US), Brainlab AG(Germany), Mirada Medical(UK), DOSIsoft SA(France), Bracco Group (Italy), Hermes Medical Solutions (Sweden), INVIA, LLC (US), Mediso Ltd. (Hungary), Canon Medical Systems Corporation (Japan), LabLogic Systems Ltd. (UK), Mirion Technologies (ec2 Software Solutions)(US), COMECER S.p.A.(Italy), RaySearch Laboratories(Sweden), UltraSPECT Inc. (US), Sectra AB (Sweden), Agfa-Gevaert Group (Belgium), Perceptive(UK). Players adopted both organic and inorganic growth strategies, including product launches and enhancements, as well as investments, partnerships, collaborations, joint ventures, funding, acquisitions, expansions, agreements, contracts, and alliances. These strategies aimed to increase their offerings, meet the unmet needs of customers, boost profitability, and expand their presence globally market. The study includes an in-depth competitive analysis of these key players in the nuclear medicine software market, with their company profiles, recent developments, and key market strategies. Research Coverage • The report studies the nuclear medicine software market based on software type, workflow, integration complexity, software licensing model, revenue model, application, therapeutic area, technology maturity, end user, and region. • The report analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth. • The report evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. • The report studies micromarkets with respect to their growth trends, prospects, and contributions to the total nuclear medicine software market. • The report forecasts the revenue of market segments with respect to five major regions. Reasons to Buy the Report The report can help established firms, as well as new entrants/smaller firms, gauge the pulse of the market, which, in turn, would help them garner a greater share. Firms purchasing the report could use one or a combination of the five strategies mentioned below. This report provides insights into the following pointers:  Analysis of key drivers (increasing demand for early and accurate diagnostics, growing focus on personalized medicine, integration of automated dosimetry tools, growing prevalence of chronic diseases and subsequent increase in clinical trials, effective monitoring of nuclear medicine software), restraints (high cost of imaging equipment, data privacy and security concerns, shortage of skilled professionals, interpolability issues), opportunities (infrastructure development, increased healthcare IT expenditure, data privacy and regulatory reforms), and challenges (compliance requirements, low penetration of advanced imaging devices, underdeveloped radiopharmcy ecosysytem, economic and financial barriers) influencing the industry macrodynamics of nuclear medicine software market.  Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and product launches in the nuclear medicine software market.  Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various types of nuclear medicine software across regions.  Market Diversification: Exhaustive information about products, untapped regions, recent developments, and investments in the nuclear medicine software market.  Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the nuclear medicine software market.
目錄 Table of Contents
1 INTRODUCTION 42 1.1 STUDY OBJECTIVES 42 1.2 MARKET DEFINITION 42 1.3 STUDY SCOPE 43 1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE 43 1.3.2 YEARS CONSIDERED 45 1.4 CURRENCY CONSIDERED 45 1.5 STAKEHOLDERS 46 1.6 LIMITATIONS 46 2 RESEARCH METHODOLOGY 47 2.1 RESEARCH APPROACH 47 2.1.1 SECONDARY RESEARCH 47 2.1.1.1 Key data from secondary sources 48 2.1.2 PRIMARY RESEARCH 49 2.1.2.1 Primary sources 49 2.1.2.2 Key data from primary sources 50 2.1.2.3 Breakdown of primaries 50 2.1.2.4 Insights from primary experts 51 2.2 RESEARCH METHODOLOGY DESIGN 51 2.3 MARKET SIZE ESTIMATION 52 2.4 MARKET BREAKDOWN & DATA TRIANGULATION 57 2.5 MARKET SHARE ESTIMATION 57 2.6 STUDY ASSUMPTIONS 58 2.7 RESEARCH LIMITATIONS 58 2.7.1 METHODOLOGY-RELATED LIMITATIONS 58 2.8 RISK ASSESSMENT 58 3 EXECUTIVE SUMMARY 59 4 PREMIUM INSIGHTS 66 4.1 OVERVIEW OF NUCLEAR MEDICINE SOFTWARE MARKET 66 4.2 ASIA PACIFIC: NUCLEAR MEDICINE SOFTWARE MARKET, BY COUNTRY & INTEGRATION COMPLEXITY 67 4.3 GEOGRAPHIC SNAPSHOT OF NUCLEAR MEDICINE SOFTWARE MARKET 68 4.4 NUCLEAR MEDICINE SOFTWARE MARKET: REGIONAL MIX 68 4.5 NUCLEAR MEDICINE SOFTWARE MARKET: DEVELOPED VS. EMERGING ECONOMIES 69   5 MARKET OVERVIEW 70 5.1 INTRODUCTION 70 5.2 MARKET DYNAMICS 70 5.2.1 DRIVERS 71 5.2.1.1 Rising global disease prevalence 71 5.2.1.2 Surge in AI-powered theranostics 72 5.2.1.3 Adoption of cloud-based platforms & mobile/remote diagnostics 72 5.2.1.4 Radiopharmaceutical supply chain visibility & radiopharmaceutical software 72 5.2.1.5 Expansion of personalized medicine in nuclear applications 73 5.2.2 RESTRAINTS 73 5.2.2.1 High acquisition & total cost of ownership 73 5.2.2.2 Regulatory & approval delays with AI integration 74 5.2.2.3 Integration & interoperability challenges 74 5.2.3 OPPORTUNITIES 75 5.2.3.1 Precision & predictive dosimetry 75 5.2.3.2 Expansion of tele-nuclear medicine networks & mobile access 75 5.2.4 CHALLENGES 75 5.2.4.1 Lack of technical expertise 75 5.2.4.2 Regulatory uncertainties 76 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 76 5.4 INDUSTRY TRENDS 77 5.4.1 OVERVIEW OF USE CASES 77 5.4.2 INTEGRATION OF ARTIFICIAL INTELLIGENCE AND ADVANCED ANALYTICS 79 5.4.3 SHIFT TOWARD HYBRID AND MULTI-MODALITY IMAGING SOLUTIONS 79 5.5 ECOSYSTEM ANALYSIS 79 5.6 SUPPLY CHAIN ANALYSIS 82 5.7 TECHNOLOGY ANALYSIS 83 5.7.1 KEY TECHNOLOGIES 83 5.7.1.1 SPECT/PET image reconstruction algorithms 83 5.7.1.2 Quantitative molecular imaging tools 84 5.7.1.3 Radiopharmaceutical dosimetry software 84 5.7.1.4 Artificial intelligence and machine learning 84 5.7.1.5 Multi-modality fusion & co-registration engines 84 5.7.2 COMPLEMENTARY TECHNOLOGIES 84 5.7.2.1 DICOM AND HL7 integration engines 84 5.7.2.2 Theranostics workflow orchestration tools 85 5.7.2.3 Cloud-based PACS/archiving solutions 85 5.7.3 ADJACENT TECHNOLOGIES 85 5.7.3.1 Molecular imaging-omics integration tools 85 5.7.3.2 Blockchain 85   5.8 REGULATORY ANALYSIS 86 5.8.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 86 5.8.2 REGULATORY ANALYSIS 88 5.9 PRICING ANALYSIS 91 5.9.1 INDICATIVE PRICE FOR NUCLEAR MEDICINE SOFTWARE, BY KEY PLAYER (2024) 91 5.9.2 INDICATIVE PRICE FOR NUCLEAR MEDICINE SOFTWARE, BY REGION (2024) 92 5.9.3 PRICING MODELS (QUALITATIVE) 93 5.10 PORTER’S FIVE FORCES ANALYSIS 93 5.10.1 THREAT OF NEW ENTRANTS 95 5.10.2 THREAT OF SUBSTITUTES 95 5.10.3 BARGAINING POWER OF BUYERS 95 5.10.4 BARGAINING POWER OF SUPPLIERS 95 5.10.5 INTENSITY OF COMPETITIVE RIVALRY 95 5.11 PATENT ANALYSIS 95 5.11.1 PATENT PUBLICATION TRENDS FOR NUCLEAR MEDICINE SOFTWARE SOLUTIONS 96 5.11.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS 96 5.12 KEY STAKEHOLDERS & BUYING CRITERIA 98 5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS 98 5.12.2 BUYING CRITERIA 99 5.13 END-USER ANALYSIS 99 5.13.1 UNMET NEEDS 99 5.13.2 END-USER EXPECTATIONS 100 5.14 KEY CONFERENCES & EVENTS, 2025–2026 101 5.14.1 NUCLEAR MEDICINE SOFTWARE MARKET: DETAILED LIST OF CONFERENCES & EVENTS, 2025–2026 101 5.15 CASE STUDY ANALYSIS 103 5.15.1 ENSURING PRECISION IN NUCLEAR MEDICINE WITH NATIONAL STANDARD TRACEABILITY 103 5.15.1.1 Case 1: Strengthening quality control and patient outcomes with ANSTO’s coordinated CRM program 103 5.15.2 STREAMLINING MULTI-MODALITY IMAGE FUSION FOR BETTER DIAGNOSTICS 104 5.15.2.1 Case 2: GE HealthCare’s Xeleris platform enhances multi-modality imaging at a leading academic medical center 104 5.15.3 SUPPORTING REMOTE CONSULTATIONS WITH CLOUD-BASED NUCLEAR MEDICINE ANALYSIS 104 5.15.3.1 Case 3: Sectra’s cloud-based solution empowers remote nuclear medicine consultations for regional hospitals 104 5.16 INVESTMENT & FUNDING SCENARIO 105 5.17 BUSINESS MODEL ANALYSIS 105 5.17.1 LICENSE-BASED BUSINESS MODELS 105 5.17.2 SUBSCRIPTION-BASED BUSINESS MODELS 105 5.17.3 SOFTWARE-AS-A-SERVICE (SAAS) BUSINESS MODELS 106 5.17.4 PAY-PER-USE BUSINESS MODELS 106 5.17.5 FREEMIUM BUSINESS MODELS 106 5.17.6 INTEGRATED SERVICE AND SOFTWARE BUNDLE BUSINESS MODELS 106 5.18 IMPACT OF AI/GEN AI ON NUCLEAR MEDICINE SOFTWARE MARKET 106 5.18.1 KEY USE CASES 107 5.18.2 CASE STUDIES OF AI/GENERATIVE AI IMPLEMENTATION 108 5.18.2.1 Case study 1: AI-based low-dose PET image reconstruction 108 5.18.2.2 Case study 2: Dose-aware diffusion models for 3D low-dose PET 108 5.18.3 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS 109 5.18.3.1 Medical image analysis software 109 5.18.3.2 Radiology information systems 109 5.18.3.3 Clinical decision support systems 110 5.18.4 USER READINESS & IMPACT ASSESSMENT 110 5.18.4.1 User readiness 110 5.18.4.1.1 User A: Healthcare providers 110 5.18.4.1.2 User B: Pharmaceutical & biotechnology companies 110 5.18.4.2 Impact assessment 110 5.18.4.2.1 User A: Healthcare providers 110 5.18.4.2.1.1 Implementation 110 5.18.4.2.1.2 Impact 111 5.18.4.2.2 User B: Pharmaceutical & biotechnology companies 111 5.18.4.2.2.1 Implementation 111 5.18.4.2.2.2 Impact 111 5.19 IMPACT OF 2025 US TARIFFS ON NUCLEAR MEDICINE SOFTWARE MARKET 112 5.19.1 INTRODUCTION 112 5.19.2 KEY TARIFF RATES 113 5.19.3 PRICE IMPACT ANALYSIS 114 5.19.4 IMPACT ON COUNTRY/REGION 115 5.19.4.1 US 115 5.19.4.2 Europe 115 5.19.4.3 Asia Pacific 115 5.19.5 IMPACT ON END-USE INDUSTRIES 116 6 NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE TYPE 117 6.1 INTRODUCTION 118 6.2 IMAGE ACQUISITION & RECONSTRUCTION SOFTWARE 119 6.2.1 ABILITY TO OPTIMIZE NUCLEAR IMAGING THROUGH AI-POWERED ACQUISITION AND RECONSTRUCTION SOFTWARE TO DRIVE MARKET 119 6.3 IMAGE ANALYSIS & QUANTIFICATION SOFTWARE 120 6.3.1 AI INNOVATION, WORKFLOW OPTIMIZATION, AND PERSONALIZED CARE TRENDS TO SUPPORT GROWTH 120   6.4 WORKFLOW MANAGEMENT & ORCHESTRATION SOFTWARE 122 6.4.1 NEED FOR ADVANCING NUCLEAR MEDICINE THROUGH INTEGRATED WORKFLOW MANAGEMENT SOLUTIONS TO BOOST GROWTH 122 6.5 PACS INTEGRATION & DATA MANAGEMENT SOFTWARE 123 6.5.1 GROWING NEED FOR RADIOTRACER-AWARE ANALYTICS, COMPLIANCE, AND INTEROPERABILITY TO BOOST ADOPTION 123 6.6 REPORTING & DOCUMENTATION SOFTWARE 125 6.6.1 EXPANDING HEALTHCARE INVESTMENTS IN APAC AND MIDDLE EAST TO ACCELERATE ADOPTION OF REPORTING & DOCUMENTATION SOFTWARE 125 6.7 RADIOPHARMACEUTICAL MANAGEMENT SOFTWARE 126 6.7.1 OPERATIONAL, CLINICAL, AND REGULATORY CATALYSTS TO DRIVE MARKET GROWTH 126 6.8 DOSIMETRY & TREATMENT PLANNING SOFTWARE 128 6.8.1 PRECISION IMAGING AND AI-DRIVEN WORKFLOWS TO ADVANCE DOSIMETRY & TREATMENT PLANNING 128 6.9 QUALITY CONTROL & ASSURANCE SOFTWARE 129 6.9.1 HYBRID-IMAGING QA NEEDS, DIGITAL AUDIT READINESS, AND EDGE-BASED AI FOR OFFLINE ENVIRONMENTS TO FUEL GROWTH 129 6.10 AI & ADVANCED ANALYTICS SOFTWARE 130 6.10.1 ABILITY OF INTEGRATED AI ECOSYSTEMS TO REDEFINE NUCLEAR IMAGING EFFICIENCY TO SUPPORT MARKET 130 6.11 MOBILE & REMOTE ACCESS SOFTWARE 132 6.11.1 GROWING POPULARITY OF PORTABLE AND POINT-OF-CARE SCANNERS TO DRIVE MARKET DEMAND 132 7 NUCLEAR MEDICINE SOFTWARE MARKET, BY WORKFLOW 134 7.1 INTRODUCTION 135 7.2 IMAGE ACQUISITION 135 7.2.1 ADVANCED INNOVATIONS TRANSFORMING IMAGE ACQUISITION INTO DYNAMIC, MULTI-FUNCTIONAL COMPONENTS TO DRIVE MARKET 135 7.3 DATA PROCESSING 136 7.3.1 OPTIMIZING CLINICAL INSIGHTS WITH INTELLIGENT DATA PROCESSING IN NUCLEAR MEDICINE WORKFLOWS TO SUPPORT GROWTH 136 7.4 REPORTING 138 7.4.1 PRECISION AND EFFICIENCY ASSOCIATED WITH AI-INTEGRATED REPORTING SOLUTIONS TO TRANSFORM MARKET 138 7.5 DATA MANAGEMENT 139 7.5.1 GROWING NEED FOR ADVANCED DATA MANAGEMENT SOLUTIONS TO STREAMLINE IMAGING WORKFLOWS TO DRIVE GROWTH 139 8 NUCLEAR MEDICINE SOFTWARE MARKET, BY INTEGRATION COMPLEXITY 142 8.1 INTRODUCTION 143 8.2 STANDALONE SOLUTIONS 143 8.2.1 AVAILABILITY OF ROBUST STANDALONE SOLUTIONS TAILORED TO SPECIFIC IMAGING AND ANALYSIS NEEDS TO BOOST MARKET 143   8.3 INTEGRATED SOLUTIONS 145 8.3.1 ADVANTAGES SUCH AS REDUCED MANUAL STEPS AND IMPROVED DIAGNOSTIC ACCURACY TO DRIVE DEMAND 145 8.4 CLOUD-NATIVE PLATFORMS 146 8.4.1 ABILITY OF CLOUD-NATIVE PLATFORMS TO DRIVE SCALABLE AND CONNECTED IMAGING IN NUCLEAR MEDICINE TO DRIVE MARKET 146 9 NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE LICENSING 149 9.1 INTRODUCTION 150 9.2 PERPETUAL/TRADITIONAL LICENSES 150 9.2.1 GROWING DEMAND FOR PREDICTABLE LONG-TERM COSTS TO DRIVE ADOPTION 150 9.3 SUBSCRIPTION/SAAS LICENSES 152 9.3.1 ABILITY OF CLOUD-BASED SAAS SOLUTIONS TO ENHANCE IMAGING SCALABILITY AND EXPAND ACCESS TO FUEL GROWTH 152 9.4 USAGE-BASED LICENSES 153 9.4.1 ADVANTAGES SUCH AS SCALABLE ACCESS, REGULATORY COMPLIANCE, AND OPTIMIZED COSTS TO DRIVE DEMAND 153 9.5 ENTERPRISE AGREEMENTS 155 9.5.1 SEAMLESS DIGITAL TRANSFORMATION IN NUCLEAR MEDICINE THROUGH ENTERPRISE AGREEMENTS TO SUPPORT MARKET GROWTH 155 10 NUCLEAR MEDICINE SOFTWARE MARKET, BY REVENUE MODEL 157 10.1 INTRODUCTION 158 10.2 SOFTWARE LICENSES 158 10.2.1 ADVANTAGES SUCH AS SCALABLE, AI-POWERED, AND COMPLIANT IMAGING SOLUTIONS TO DRIVE DEMAND 158 10.3 MAINTENANCE & SUPPORT 160 10.3.1 RELIABLE DIAGNOSTICS AND MINIMIZED DOWNTIME ASSOCIATED WITH MAINTENANCE & SUPPORT SERVICES TO BOOST MARKET 160 10.4 PROFESSIONAL SERVICES 161 10.4.1 OPTIMIZING PHARMACY OPERATIONS THROUGH COMPREHENSIVE AUTOMATION SERVICES TO DRIVE GROWTH 161 10.5 CLOUD SERVICES 163 10.5.1 ACCELERATING NUCLEAR MEDICINE TRANSFORMATION THROUGH CLOUD-DRIVEN IMAGING AND AI INTEGRATION TO BOOST MARKET 163 11 NUCLEAR MEDICINE SOFTWARE MARKET, BY APPLICATION 165 11.1 INTRODUCTION 166 11.2 DIAGNOSTICS 166 11.2.1 AUTOMATED IMAGE INTERPRETATION 168 11.2.1.1 Ability of AI-powered automated interpretation tools to streamline imaging workflows and reduce variability to boost adoption 168 11.2.2 TUMOR SEGMENTATION & QUANTIFICATION 169 11.2.2.1 Advancing precision oncology through AI-powered tumor segmentation solutions to support market growth 169 11.3 THERAPEUTICS 170 11.3.1 PREDICTIVE ANALYTICS 171 11.3.1.1 Advantages such as enhanced dosimetry accuracy and improved clinical outcomes to drive growth 171 11.3.2 WORKFLOW OPTIMIZATION & QUALITY CONTROL 172 11.3.2.1 Ability of workflow optimization and quality control solutions to enhance operational efficiency to boost market 172 11.3.3 PERSONALIZED DOSIMETRY CALCULATIONS 173 11.3.3.1 Optimized radiation delivery and standardized nuclear medicine workflows to drive demand 173 11.3.4 THERANOSTICS 174 11.3.4.1 Advantages such as real-time treatment optimization in nuclear medicine to drive popularity of theranostics 174 11.4 EMERGENCY & STAT WORKFLOWS 174 11.4.1 NEED TO ACCELERATE CRITICAL CARE DELIVERY WITH AI-DRIVEN NUCLEAR MEDICINE SOFTWARE SOLUTIONS TO PROPEL MARKET 174 11.5 CLINICAL RESEARCH 176 11.5.1 GROWING DEMAND FOR SCALABLE SERVICE SOLUTIONS THAT STREAMLINE IT DEPLOYMENT TO FURTHER MARKET GROWTH 176 12 NUCLEAR MEDICINE SOFTWARE MARKET, BY THERAPEUTIC AREA 179 12.1 INTRODUCTION 180 12.2 ONCOLOGY 180 12.2.1 GROWING NEED FOR CANCER DETECTION AND THERAPY PLANNING THROUGH MOLECULAR IMAGING MODALITIES TO DRIVE GROWTH 180 12.3 NEUROLOGY 182 12.3.1 ADVANTAGES SUCH AS EARLY DETECTION, FUNCTIONAL BRAIN MAPPING, AND AUTOMATED DISEASE TRACKING TO DRIVE DEMAND 182 12.4 CARDIOLOGY 183 12.4.1 NEED TO TRANSFORM CARDIAC NUCLEAR IMAGING WITH SMART TECHNOLOGIES TO BOOST GROWTH 183 12.5 OTHER THERAPEUTIC AREAS 185 13 NUCLEAR MEDICINE SOFTWARE MARKET, BY TECHNOLOGY MATURITY 187 13.1 INTRODUCTION 188 13.2 UPCOMING TECHNOLOGIES 188 13.2.1 AI & ADVANCED ANALYTICS 190 13.2.1.1 High burden of neurodegenerative diseases and oncology imaging complexity to boost market 190 13.2.2 DOSIMETRY & TREATMENT PLANNING 191 13.2.2.1 Rise of radioligand therapies like lutetium-177 to increase dosimetry software adoption 191 13.2.3 CLOUD-NATIVE PLATFORMS 192 13.2.3.1 Scalable AI-integrated nuclear medicine solutions with remote accessibility to drive nuclear medicine software growth 192   13.2.4 MOBILE & REMOTE ACCESS 193 13.2.4.1 Growing use of portable imaging devices, hybrid care demands, and supportive reimbursement trends to support market growth 193 13.3 MATURE TECHNOLOGIES 194 13.3.1 IMAGE ACQUISITION & RECONSTRUCTION 195 13.3.1.1 Ability of image reconstruction to drive precision and low-dose imaging in nuclear medicine to boost market 195 13.3.2 PACS INTEGRATION 196 13.3.2.1 Rise of hybrid imaging, need for SUV harmonization, and increasing regulatory focus on dosimetry to propel market 196 13.3.3 QUALITY CONTROL 197 13.3.3.1 Advancing quality control through standardized reconstruction in nuclear medicine to aid growth 197 14 NUCLEAR MEDICINE SOFTWARE MARKET, BY END USER 199 14.1 INTRODUCTION 200 14.2 HEALTHCARE PROVIDERS 200 14.2.1 HOSPITALS 202 14.2.1.1 Ability of hospitals to drive diagnostic precision and workflow efficiency in nuclear medicine to boost market 202 14.2.2 OUTPATIENT SETTINGS 203 14.2.2.1 Need for accessibility, efficiency, and growth in nuclear medicine software to boost adoption 203 14.2.3 DIAGNOSTIC & IMAGING CENTERS 204 14.2.3.1 Expanding access and precision in nuclear diagnostics to support market growth 204 14.2.4 RADIOPHARMACIES 205 14.2.4.1 Accelerating radiopharmaceutical precision and safety through radiopharmacy software innovations to fuel growth 205 14.2.5 OTHER HEALTHCARE PROVIDERS 206 14.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 207 14.3.1 EXPANDING INFLUENCE OF NUCLEAR MEDICINE SOFTWARE IN RADIOPHARMACEUTICAL R&D AND CLINICAL TRIALS TO BOOST MARKET 207 14.4 MEDTECH COMPANIES 209 14.4.1 NEED TO ADVANCE NUCLEAR IMAGING TRIALS WITH PRECISION SOFTWARE INTEGRATION TO PROPEL MARKET 209 14.5 OTHER END USERS 210 15 NUCLEAR MEDICINE SOFTWARE MARKET, BY REGION 212 15.1 INTRODUCTION 213 15.2 NORTH AMERICA 213 15.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 214 15.2.2 US 221 15.2.2.1 Emergence of hybrid imaging systems with enhanced diagnostic accuracy to drive market growth 221 15.2.3 CANADA 227 15.2.3.1 Government initiatives and funding to support market growth 227 15.3 EUROPE 233 15.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 233 15.3.2 GERMANY 240 15.3.2.1 Rising theranostic procedures to drive demand for advanced dosimetry and imaging software 240 15.3.3 UK 246 15.3.3.1 Infrastructure expansion and digital health initiatives to advance market growth 246 15.3.4 FRANCE 252 15.3.4.1 Accelerated digital transformation and expansion of targeted radiotherapy to drive growth 252 15.3.5 ITALY 258 15.3.5.1 Growing need for tailored diagnostics to drive nuclear medicine software market growth 258 15.3.6 SPAIN 264 15.3.6.1 Targeted public investments to drive advancements in nuclear medicine software 264 15.3.7 REST OF EUROPE 270 15.4 ASIA PACIFIC 276 15.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 276 15.4.2 JAPAN 284 15.4.2.1 Deeply ingrained culture of technological advancements in healthcare and medical imaging to support market 284 15.4.3 CHINA 290 15.4.3.1 China’s strategy for healthcare modernization and technological independence to boost growth 290 15.4.4 INDIA 296 15.4.4.1 Steady growth in number of nuclear medicine facilities and SPECT/PET equipment to fuel growth 296 15.4.5 REST OF ASIA PACIFIC 302 15.5 LATIN AMERICA 307 15.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 307 15.5.2 BRAZIL 314 15.5.2.1 Improving healthcare infrastructure to boost procedural volume 314 15.5.3 MEXICO 320 15.5.3.1 Increasing focus on digital transformation within healthcare system to support market growth 320 15.5.4 REST OF LATIN AMERICA 326 15.6 MIDDLE EAST & AFRICA 331 15.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 331 15.6.2 GCC COUNTRIES 338 15.6.2.1 Substantial investments and national visions to transform market 338 15.6.3 REST OF MIDDLE EAST & AFRICA 344 16 COMPETITIVE LANDSCAPE 350 16.1 OVERVIEW 350 16.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 350 16.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN NUCLEAR MEDICINE SOFTWARE MARKET 351 16.3 REVENUE ANALYSIS, 2020–2024 353 16.4 MARKET SHARE ANALYSIS, 2024 354 16.4.1 GLOBAL MARKET SHARE ANALYSIS FOR PET (POSITRON EMISSION TOMOGRAPHY) 357 16.4.2 GLOBAL MARKET SHARE ANALYSIS FOR SPECT (SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY) 359 16.5 BRAND/PRODUCT COMPARISON 361 16.6 COMPANY VALUATION & FINANCIAL METRICS 362 16.6.1 FINANCIAL METRICS 362 16.6.2 COMPANY VALUATION 362 16.7 MARKET RANKING ANALYSIS 363 16.8 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 363 16.8.1 STARS 363 16.8.2 EMERGING LEADERS 363 16.8.3 PERVASIVE PLAYERS 364 16.8.4 PARTICIPANTS 364 16.8.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 365 16.8.5.1 Company footprint 365 16.8.5.2 Region footprint 366 16.8.5.3 Software type footprint 367 16.8.5.4 Workflow footprint 368 16.8.5.5 Integration complexity footprint 369 16.8.5.6 Application footprint 370 16.8.5.7 Therapeutic area footprint 371 16.8.5.8 End-user footprint 372 16.9 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 373 16.9.1 PROGRESSIVE COMPANIES 373 16.9.2 RESPONSIVE COMPANIES 373 16.9.3 DYNAMIC COMPANIES 373 16.9.4 STARTING BLOCKS 373 16.9.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 375 16.9.5.1 Detailed list of key startups/SMEs 375 16.9.5.2 Competitive benchmarking of startups/SMEs 375 16.10 COMPETITIVE SCENARIO 377 16.10.1 PRODUCT LAUNCHES & APPROVALS 377 16.10.2 DEALS 378 16.10.3 EXPANSIONS 380 16.10.4 OTHER DEVELOPMENTS 380 17 COMPANY PROFILES 381 17.1 KEY PLAYERS 381 17.1.1 GE HEALTHCARE 381 17.1.1.1 Business overview 381 17.1.1.2 Products & services offered 382 17.1.1.3 Recent developments 384 17.1.1.3.1 Product launches & approvals 384 17.1.1.3.2 Deals 384 17.1.1.3.3 Expansions 387 17.1.1.4 MnM view 387 17.1.1.4.1 Right to win 387 17.1.1.4.2 Strategic choices 387 17.1.1.4.3 Weaknesses & competitive threats 388 17.1.2 SIEMENS HEALTHINEERS AG 389 17.1.2.1 Business overview 389 17.1.2.2 Products & services offered 390 17.1.2.3 Recent developments 392 17.1.2.3.1 Product launches 392 17.1.2.3.2 Deals 393 17.1.2.4 MnM view 393 17.1.2.4.1 Right to win 393 17.1.2.4.2 Strategic choices 394 17.1.2.4.3 Weaknesses & competitive threats 394 17.1.3 KONINKLIJKE PHILIPS N.V. 395 17.1.3.1 Business overview 395 17.1.3.2 Products & services offered 396 17.1.3.3 Recent developments 397 17.1.3.3.1 Product launches 397 17.1.3.4 MnM view 398 17.1.3.4.1 Right to win 398 17.1.3.4.2 Strategic choices 398 17.1.3.4.3 Weaknesses & competitive threats 398 17.1.4 LANTHEUS 399 17.1.4.1 Business overview 399 17.1.4.2 Products & services offered 400 17.1.4.3 Recent developments 401 17.1.4.3.1 Deals 401 17.1.4.3.2 Other developments 401 17.1.4.4 MnM view 402 17.1.4.4.1 Right to win 402 17.1.4.4.2 Strategic choices 402 17.1.4.4.3 Weaknesses & competitive threats 403 17.1.5 CANON MEDICAL SYSTEMS CORPORATION 404 17.1.5.1 Business overview 404 17.1.5.2 Products & services offered 405 17.1.5.3 Recent developments 406 17.1.5.3.1 Deals 406 17.1.5.4 MnM view 406 17.1.5.4.1 Right to win 406 17.1.5.4.2 Strategic choices 406 17.1.5.4.3 Weaknesses & competitive threats 407 17.1.6 MIRION TECHNOLOGIES, INC. 408 17.1.6.1 Business overview 408 17.1.6.2 Products & services offered 409 17.1.6.3 Recent developments 411 17.1.6.3.1 Product launches 411 17.1.6.3.2 Deals 411 17.1.6.4 MnM view 412 17.1.6.4.1 Right to win 412 17.1.6.4.2 Strategic choices 412 17.1.6.4.3 Weaknesses & competitive threats 412 17.1.7 BRAINLAB AG 413 17.1.7.1 Business overview 413 17.1.7.2 Products & services offered 413 17.1.7.3 Recent developments 414 17.1.7.3.1 Product approvals 414 17.1.8 MIRADA MEDICAL LIMITED 415 17.1.8.1 Business overview 415 17.1.8.2 Products & services offered 415 17.1.8.3 Recent developments 416 17.1.8.3.1 Product approvals 416 17.1.8.3.2 Deals 416 17.1.9 DOSISOFT SA 418 17.1.9.1 Business overview 418 17.1.9.2 Products & services offered 418 17.1.9.3 Recent developments 419 17.1.9.3.1 Product approvals 419 17.1.9.3.2 Deals 419 17.1.10 BRACCO GROUP 420 17.1.10.1 Business overview 420 17.1.10.2 Products & services offered 421 17.1.10.3 Recent developments 421 17.1.10.3.1 Product launches & approvals 421 17.1.11 HERMES MEDICAL SOLUTIONS 422 17.1.11.1 Business overview 422 17.1.11.2 Products & services offered 423 17.1.11.3 Recent developments 424 17.1.11.3.1 Product launches & approvals 424 17.1.11.3.2 Deals 425 17.1.12 INVIA, LLC 426 17.1.12.1 Business overview 426 17.1.12.2 Products & services offered 426 17.1.12.3 Recent developments 427 17.1.12.3.1 Product launches 427 17.1.12.3.2 Deals 427 17.1.13 MEDISO LTD. 428 17.1.13.1 Business overview 428 17.1.13.2 Products & services offered 429 17.1.13.3 Recent developments 430 17.1.13.3.1 Product launches & approvals 430 17.1.14 LABLOGIC SYSTEMS LTD. 431 17.1.14.1 Business overview 431 17.1.14.2 Products & services offered 432 17.1.14.3 Recent developments 433 17.1.14.3.1 Product approvals 433 17.1.15 COMECER S.P.A. PRIVATE 434 17.1.15.1 Business overview 434 17.1.15.2 Products & services offered 435 17.1.15.3 Recent developments 436 17.1.15.3.1 Product updates 436 17.1.15.3.2 Deals 436 17.1.16 RAYSEARCH LABORATORIES 437 17.1.16.1 Business overview 437 17.1.16.2 Products & services offered 438 17.1.16.3 Recent developments 439 17.1.16.3.1 Product launches 439 17.1.17 ULTRASPECT INC. 440 17.1.17.1 Business overview 440 17.1.17.2 Products & services offered 441 17.1.18 SECTRA AB 442 17.1.18.1 Business overview 442 17.1.18.2 Products & services offered 443 17.1.18.3 Recent developments 444 17.1.18.3.1 Product launches 444 17.1.18.3.2 Deals 444 17.1.19 AGFA-GEVAERT GROUP 445 17.1.19.1 Business overview 445 17.1.19.2 Products & services offered 446 17.1.20 PERCEPTIVE 447 17.1.20.1 Business overview 447 17.1.20.2 Products & services offered 447 17.1.20.3 Recent developments 448 17.1.20.3.1 Product launches 448 17.1.20.3.2 Deals 448 17.2 OTHER PLAYERS 449 17.2.1 SYNTERMED INC. 449 17.2.2 SEGAMI CORPORATION 450 17.2.3 VERSANT MEDICAL PHYSICS & RADIATION SAFETY 451 17.2.4 PIXMEO 452 17.2.5 PAIRE 453 17.2.6 SUBTLE MEDICAL, INC. 454 18 APPENDIX 455 18.1 DISCUSSION GUIDE 455 18.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 461 18.3 CUSTOMIZATION OPTIONS 463 18.4 RELATED REPORTS 463 18.5 AUTHOR DETAILS 464
圖表清單 List of Tables & Figures
TABLE 1 INCLUSIONS & EXCLUSIONS 44 TABLE 2 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD 45 TABLE 3 RISK ASSESSMENT: NUCLEAR MEDICINE SOFTWARE MARKET 58 TABLE 4 NUCLEAR MEDICINE SOFTWARE MARKET: IMPACT ANALYSIS 71 TABLE 5 NUCLEAR MEDICINE SOFTWARE MARKET: ROLE IN ECOSYSTEM 81 TABLE 6 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 86 TABLE 7 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 86 TABLE 8 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 87 TABLE 9 REGULATORY STANDARDS IN NUCLEAR MEDICINE 88 TABLE 10 REGULATORY REQUIREMENTS IN NORTH AMERICA 88 TABLE 11 REGULATORY REQUIREMENTS IN EUROPE 89 TABLE 12 REGULATORY REQUIREMENTS IN ASIA PACIFIC 89 TABLE 13 REGULATORY REQUIREMENTS IN LATIN AMERICA 90 TABLE 14 REGULATORY REQUIREMENTS IN MIDDLE EAST & AFRICA 90 TABLE 15 INDICATIVE PRICE FOR NUCLEAR MEDICINE SOFTWARE, BY KEY PLAYER (2024) 92 TABLE 16 AVERAGE SELLING PRICE OF NUCLEAR CARDIOLOGY REPORTING SOFTWARE (2024) 92 TABLE 17 INDICATIVE PRICE FOR NUCLEAR MEDICINE SOFTWARE, BY REGION (2024) 93 TABLE 18 NUCLEAR MEDICINE SOFTWARE MARKET: PORTER’S FIVE FORCES ANALYSIS 94 TABLE 19 JURISDICTION ANALYSIS OF TOP APPLICANT COUNTRIES FOR NUCLEAR MEDICINE SOFTWARE SOLUTIONS 96 TABLE 20 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS (%) 98 TABLE 21 KEY BUYING CRITERIA FOR END USERS 99 TABLE 22 UNMET NEEDS IN NUCLEAR MEDICINE SOFTWARE MARKET 100 TABLE 23 END-USER EXPECTATIONS IN NUCLEAR MEDICINE SOFTWARE MARKET 101 TABLE 24 US-ADJUSTED RECIPROCAL TARIFF RATES 113 TABLE 25 NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE TYPE, 2023–2030 (USD MILLION) 118 TABLE 26 NUCLEAR MEDICINE SOFTWARE MARKET FOR IMAGE ACQUISITION & RECONSTRUCTION SOFTWARE: MAJOR PLAYERS AND OFFERINGS 120 TABLE 27 NUCLEAR MEDICINE SOFTWARE MARKET FOR IMAGE ACQUISITION & RECONSTRUCTION SOFTWARE, BY REGION, 2023–2030 (USD MILLION) 120 TABLE 28 NUCLEAR MEDICINE SOFTWARE MARKET FOR IMAGE ANALYSIS & QUANTIFICATION SOFTWARE: MAJOR PLAYERS AND OFFERINGS 121 TABLE 29 NUCLEAR MEDICINE SOFTWARE MARKET FOR IMAGE ANALYSIS & QUANTIFICATION SOFTWARE, BY REGION, 2023–2030 (USD MILLION) 122 TABLE 30 NUCLEAR MEDICINE SOFTWARE MARKET FOR WORKFLOW MANAGEMENT & ORCHESTRATION SOFTWARE: MAJOR PLAYERS AND OFFERINGS 123 TABLE 31 NUCLEAR MEDICINE SOFTWARE MARKET FOR WORKFLOW MANAGEMENT & ORCHESTRATION SOFTWARE, BY REGION, 2023–2030 (USD MILLION) 123 TABLE 32 NUCLEAR MEDICINE SOFTWARE MARKET FOR PACS INTEGRATION & DATA MANAGEMENT SOFTWARE: MAJOR PLAYERS AND OFFERINGS 124 TABLE 33 NUCLEAR MEDICINE SOFTWARE MARKET FOR PACS INTEGRATION & DATA MANAGEMENT SOFTWARE, BY REGION, 2023–2030 (USD MILLION) 125 TABLE 34 NUCLEAR MEDICINE SOFTWARE MARKET FOR REPORTING & DOCUMENTATION SOFTWARE: MAJOR PLAYERS AND OFFERINGS 126 TABLE 35 NUCLEAR MEDICINE SOFTWARE MARKET FOR REPORTING & DOCUMENTATION SOFTWARE, BY REGION, 2023–2030 (USD MILLION) 126 TABLE 36 NUCLEAR MEDICINE SOFTWARE MARKET FOR RADIOPHARMACEUTICAL MANAGEMENT SOFTWARE: MAJOR PLAYERS AND OFFERINGS 127 TABLE 37 NUCLEAR MEDICINE SOFTWARE MARKET FOR RADIOPHARMACEUTICAL MANAGEMENT SOFTWARE, BY REGION, 2023–2030 (USD MILLION) 127 TABLE 38 NUCLEAR MEDICINE SOFTWARE MARKET FOR DOSIMETRY & TREATMENT PLANNING SOFTWARE: MAJOR PLAYERS AND OFFERINGS 128 TABLE 39 NUCLEAR MEDICINE SOFTWARE MARKET FOR DOSIMETRY & TREATMENT PLANNING SOFTWARE, BY REGION, 2023–2030 (USD MILLION) 129 TABLE 40 NUCLEAR MEDICINE SOFTWARE MARKET FOR QUALITY CONTROL & ASSURANCE SOFTWARE: MAJOR PLAYERS AND OFFERINGS 130 TABLE 41 NUCLEAR MEDICINE SOFTWARE MARKET FOR QUALITY CONTROL & ASSURANCE SOFTWARE, BY REGION, 2023–2030 (USD MILLION) 130 TABLE 42 NUCLEAR MEDICINE SOFTWARE MARKET FOR AI & ADVANCED ANALYTICS SOFTWARE: MAJOR PLAYERS AND OFFERINGS 131 TABLE 43 NUCLEAR MEDICINE SOFTWARE MARKET FOR AI & ADVANCED ANALYTICS SOFTWARE, BY REGION, 2023–2030 (USD MILLION) 132 TABLE 44 NUCLEAR MEDICINE SOFTWARE MARKET FOR MOBILE & REMOTE ACCESS SOFTWARE: MAJOR PLAYERS AND OFFERINGS 133 TABLE 45 NUCLEAR MEDICINE SOFTWARE MARKET FOR MOBILE & REMOTE ACCESS SOFTWARE, BY REGION, 2023–2030 (USD MILLION) 133 TABLE 46 NUCLEAR MEDICINE SOFTWARE MARKET, BY WORKFLOW, 2023–2030 (USD MILLION) 135 TABLE 47 NUCLEAR MEDICINE SOFTWARE MARKET FOR IMAGE ACQUISITION WORKFLOWS: MAJOR PLAYERS AND OFFERINGS 136 TABLE 48 NUCLEAR MEDICINE SOFTWARE MARKET FOR IMAGE ACQUISITION WORKFLOWS, BY REGION, 2023–2030 (USD MILLION) 136 TABLE 49 NUCLEAR MEDICINE SOFTWARE MARKET FOR DATA PROCESSING WORKFLOWS: MAJOR PLAYERS AND OFFERINGS 137 TABLE 50 NUCLEAR MEDICINE SOFTWARE MARKET FOR DATA PROCESSING WORKFLOWS, BY REGION, 2023–2030 (USD MILLION) 138 TABLE 51 NUCLEAR MEDICINE SOFTWARE MARKET FOR REPORTING WORKFLOWS: MAJOR PLAYERS AND OFFERINGS 139 TABLE 52 NUCLEAR MEDICINE SOFTWARE MARKET FOR REPORTING WORKFLOWS, BY REGION, 2023–2030 (USD MILLION) 139 TABLE 53 NUCLEAR MEDICINE SOFTWARE MARKET FOR DATA MANAGEMENT WORKFLOWS: MAJOR PLAYERS AND OFFERINGS 140 TABLE 54 NUCLEAR MEDICINE SOFTWARE MARKET FOR DATA MANAGEMENT WORKFLOWS, BY REGION, 2023–2030 (USD MILLION) 141 TABLE 55 NUCLEAR MEDICINE SOFTWARE MARKET, BY INTEGRATION COMPLEXITY, 2023–2030 (USD MILLION) 143 TABLE 56 NUCLEAR MEDICINE SOFTWARE MARKET FOR STANDALONE SOLUTIONS: MAJOR PLAYERS AND OFFERINGS 144 TABLE 57 NUCLEAR MEDICINE SOFTWARE MARKET FOR STANDALONE SOLUTIONS, BY REGION, 2023–2030 (USD MILLION) 145 TABLE 58 NUCLEAR MEDICINE SOFTWARE MARKET FOR INTEGRATED SOLUTIONS: MAJOR PLAYERS AND OFFERINGS 146 TABLE 59 NUCLEAR MEDICINE SOFTWARE MARKET FOR INTEGRATED SOLUTIONS, BY REGION, 2023–2030 (USD MILLION) 146 TABLE 60 NUCLEAR MEDICINE SOFTWARE MARKET FOR CLOUD-NATIVE PLATFORMS: MAJOR PLAYERS AND OFFERINGS 147 TABLE 61 NUCLEAR MEDICINE SOFTWARE MARKET FOR CLOUD-NATIVE PLATFORMS, BY REGION, 2023–2030 (USD MILLION) 148 TABLE 62 NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE LICENSING, 2023–2030 (USD MILLION) 150 TABLE 63 NUCLEAR MEDICINE SOFTWARE MARKET FOR PERPETUAL/TRADITIONAL LICENSES: MAJOR PLAYERS AND OFFERINGS 151 TABLE 64 NUCLEAR MEDICINE SOFTWARE MARKET FOR PERPETUAL/TRADITIONAL LICENSES, BY REGION, 2023–2030 (USD MILLION) 152 TABLE 65 NUCLEAR MEDICINE SOFTWARE MARKET FOR SUBSCRIPTION/SAAS LICENSES: MAJOR PLAYERS AND OFFERINGS 153 TABLE 66 NUCLEAR MEDICINE SOFTWARE MARKET FOR SUBSCRIPTION/SAAS LICENSES, BY REGION, 2023–2030 (USD MILLION) 153 TABLE 67 NUCLEAR MEDICINE SOFTWARE MARKET FOR USAGE-BASED LICENSES: MAJOR PLAYERS AND OFFERINGS 154 TABLE 68 NUCLEAR MEDICINE SOFTWARE MARKET FOR USAGE-BASED LICENSES, BY REGION, 2023–2030 (USD MILLION) 155 TABLE 69 NUCLEAR MEDICINE SOFTWARE MARKET FOR ENTERPRISE AGREEMENTS: MAJOR PLAYERS AND OFFERINGS 156 TABLE 70 NUCLEAR MEDICINE SOFTWARE MARKET FOR ENTERPRISE AGREEMENTS, BY REGION, 2023–2030 (USD MILLION) 156 TABLE 71 NUCLEAR MEDICINE SOFTWARE MARKET, BY REVENUE MODEL, 2023–2030 (USD MILLION) 158 TABLE 72 NUCLEAR MEDICINE SOFTWARE MARKET FOR SOFTWARE LICENSES: MAJOR PLAYERS AND OFFERINGS 159 TABLE 73 NUCLEAR MEDICINE SOFTWARE MARKET FOR SOFTWARE LICENSES, BY REGION, 2023–2030 (USD MILLION) 159 TABLE 74 NUCLEAR MEDICINE SOFTWARE MARKET FOR MAINTENANCE & SUPPORT SERVICES: MAJOR PLAYERS AND OFFERINGS 160 TABLE 75 NUCLEAR MEDICINE SOFTWARE MARKET FOR MAINTENANCE & SUPPORT, BY REGION, 2023–2030 (USD MILLION) 161 TABLE 76 NUCLEAR MEDICINE SOFTWARE MARKET FOR PROFESSIONAL SERVICES: MAJOR PLAYERS AND OFFERINGS 162 TABLE 77 NUCLEAR MEDICINE SOFTWARE MARKET FOR PROFESSIONAL SERVICES, BY REGION, 2023–2030 (USD MILLION) 163 TABLE 78 NUCLEAR MEDICINE SOFTWARE MARKET FOR CLOUD SERVICES: MAJOR PLAYERS AND OFFERINGS 164 TABLE 79 NUCLEAR MEDICINE SOFTWARE MARKET FOR CLOUD SERVICES, BY REGION, 2023–2030 (USD MILLION) 164 TABLE 80 NUCLEAR MEDICINE SOFTWARE MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 166 TABLE 81 NUCLEAR MEDICINE SOFTWARE MARKET FOR DIAGNOSTIC APPLICATIONS: MAJOR PLAYERS AND OFFERINGS 167 TABLE 82 NUCLEAR MEDICINE SOFTWARE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 167 TABLE 83 NUCLEAR MEDICINE SOFTWARE MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2023–2030 (USD MILLION) 167 TABLE 84 NUCLEAR MEDICINE SOFTWARE MARKET FOR AUTOMATED IMAGE INTERPRETATION, BY REGION, 2023–2030 (USD MILLION) 168 TABLE 85 NUCLEAR MEDICINE SOFTWARE MARKET FOR TUMOR SEGMENTATION & QUANTIFICATION, BY REGION, 2023–2030 (USD MILLION) 169 TABLE 86 NUCLEAR MEDICINE SOFTWARE MARKET FOR THERAPEUTIC APPLICATIONS: MAJOR PLAYERS AND OFFERINGS 170 TABLE 87 NUCLEAR MEDICINE SOFTWARE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 171 TABLE 88 NUCLEAR MEDICINE SOFTWARE MARKET FOR THERAPEUTIC APPLICATIONS, BY REGION, 2023–2030 (USD MILLION) 171 TABLE 89 NUCLEAR MEDICINE SOFTWARE MARKET FOR PREDICTIVE ANALYTICS, BY REGION, 2023–2030 (USD MILLION) 172 TABLE 90 NUCLEAR MEDICINE SOFTWARE MARKET FOR WORKFLOW OPTIMIZATION & QUALITY CONTROL, BY REGION, 2023–2030 (USD MILLION) 173 TABLE 91 NUCLEAR MEDICINE SOFTWARE MARKET FOR PERSONALIZED DOSIMETRY CALCULATIONS, BY REGION, 2023–2030 (USD MILLION) 173 TABLE 92 NUCLEAR MEDICINE SOFTWARE MARKET FOR THERANOSTICS, BY REGION, 2023–2030 (USD MILLION) 174 TABLE 93 NUCLEAR MEDICINE SOFTWARE MARKET FOR EMERGENCY STAT WORKFLOWS: MAJOR PLAYERS AND OFFERINGS 176 TABLE 94 NUCLEAR MEDICINE SOFTWARE MARKET FOR EMERGENCY STAT WORKFLOWS, BY REGION, 2023–2030 (USD MILLION) 176 TABLE 95 NUCLEAR MEDICINE SOFTWARE MARKET FOR CLINICAL RESEARCH APPLICATIONS: MAJOR PLAYERS AND OFFERINGS 178 TABLE 96 NUCLEAR MEDICINE SOFTWARE MARKET FOR CLINICAL RESEARCH APPLICATIONS, BY REGION, 2023–2030 (USD MILLION) 178 TABLE 97 NUCLEAR MEDICINE SOFTWARE MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 180 TABLE 98 NUCLEAR MEDICINE SOFTWARE MARKET FOR ONCOLOGY: MAJOR PLAYERS AND OFFERINGS 181 TABLE 99 NUCLEAR MEDICINE SOFTWARE MARKET FOR ONCOLOGY, BY REGION, 2023–2030 (USD MILLION) 181 TABLE 100 NUCLEAR MEDICINE SOFTWARE MARKET FOR NEUROLOGY: MAJOR PLAYERS AND OFFERINGS 182 TABLE 101 NUCLEAR MEDICINE SOFTWARE MARKET FOR NEUROLOGY, BY REGION, 2023–2030 (USD MILLION) 183 TABLE 102 NUCLEAR MEDICINE SOFTWARE MARKET FOR CARDIOLOGY: MAJOR PLAYERS AND OFFERINGS 184 TABLE 103 NUCLEAR MEDICINE SOFTWARE MARKET FOR CARDIOLOGY, BY REGION, 2023–2030 (USD MILLION) 184 TABLE 104 NUCLEAR MEDICINE SOFTWARE MARKET FOR OTHER THERAPEUTIC AREAS: MAJOR PLAYERS AND OFFERINGS 185 TABLE 105 NUCLEAR MEDICINE SOFTWARE MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2023–2030 (USD MILLION) 186 TABLE 106 NUCLEAR MEDICINE SOFTWARE MARKET, BY TECHNOLOGY MATURITY, 2023–2030 (USD MILLION) 188 TABLE 107 NUCLEAR MEDICINE SOFTWARE MARKET FOR UPCOMING TECHNOLOGIES: MAJOR PLAYERS AND OFFERINGS 189 TABLE 108 NUCLEAR MEDICINE SOFTWARE MARKET FOR UPCOMING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 189 TABLE 109 NUCLEAR MEDICINE SOFTWARE MARKET FOR UPCOMING TECHNOLOGIES, BY REGION, 2023–2030 (USD MILLION) 190 TABLE 110 NUCLEAR MEDICINE SOFTWARE MARKET FOR AI & ADVANCED ANALYTICS, BY REGION, 2023–2030 (USD MILLION) 191 TABLE 111 NUCLEAR MEDICINE SOFTWARE MARKET FOR DOSIMETRY & TREATMENT PLANNING, BY REGION, 2023–2030 (USD MILLION) 192 TABLE 112 NUCLEAR MEDICINE SOFTWARE MARKET FOR CLOUD-NATIVE PLATFORMS TECHNOLOGY, BY REGION, 2023–2030 (USD MILLION) 193 TABLE 113 NUCLEAR MEDICINE SOFTWARE MARKET FOR MOBILE & REMOTE ACCESS, BY REGION, 2023–2030 (USD MILLION) 194 TABLE 114 NUCLEAR MEDICINE SOFTWARE MARKET FOR MATURE TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 195 TABLE 115 NUCLEAR MEDICINE SOFTWARE MARKET FOR MATURE TECHNOLOGIES, BY REGION, 2023–2030 (USD MILLION) 195 TABLE 116 NUCLEAR MEDICINE SOFTWARE MARKET FOR IMAGE ACQUISITION & RECONSTRUCTION, BY REGION, 2023–2030 (USD MILLION) 196 TABLE 117 NUCLEAR MEDICINE SOFTWARE MARKET FOR PACS INTEGRATION, BY REGION, 2023–2030 (USD MILLION) 197 TABLE 118 NUCLEAR MEDICINE SOFTWARE MARKET FOR QUALITY CONTROL, BY REGION, 2023–2030 (USD MILLION) 198 TABLE 119 NUCLEAR MEDICINE SOFTWARE MARKET, BY END USER, 2023–2030 (USD MILLION) 200 TABLE 120 NUCLEAR MEDICINE SOFTWARE MARKET FOR HEALTHCARE PROVIDERS: MAJOR PLAYERS AND OFFERINGS 201 TABLE 121 NUCLEAR MEDICINE SOFTWARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023–2030 (USD MILLION) 201 TABLE 122 NUCLEAR MEDICINE SOFTWARE MARKET FOR HEALTHCARE PROVIDERS, BY REGION, 2023–2030 (USD MILLION) 202 TABLE 123 NUCLEAR MEDICINE SOFTWARE MARKET FOR HOSPITALS, BY REGION, 2023–2030 (USD MILLION) 203 TABLE 124 NUCLEAR MDICINE SOFTWARE MARKET FOR OUTPATIENT SETTINGS, BY REGION, 2023–2030 (USD MILLION) 204 TABLE 125 NUCLEAR MEDICINE SOFTWARE MARKET FOR DIAGNOSTIC & IMAGING CENTERS, BY REGION, 2023–2030 (USD MILLION) 204 TABLE 126 NUCLEAR MDICINE SOFTWARE MARKET FOR RADIOPHARMACIES, BY REGION, 2023–2030 (USD MILLION) 205 TABLE 127 NUCLEAR MEDICINE SOFTWARE MARKET FOR OTHER HEALTHCARE ROVIDERS, BY REGION, 2023–2030 (USD MILLION) 206 TABLE 128 NUCLEAR MEDICINE SOFTWARE MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES: MAJOR PLAYERS AND OFFERINGS 208 TABLE 129 NUCLEAR MEDICINE SOFTWARE MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION) 208 TABLE 130 NUCLEAR MEDICINE SOFTWARE MARKET FOR MEDTECH COMPANIES: MAJOR PLAYERS AND OFFERINGS 209 TABLE 131 NUCLEAR MEDICINE SOFTWARE MARKET FOR MEDTECH COMPANIES, BY REGION, 2023–2030 (USD MILLION) 210 TABLE 132 NUCLEAR MEDICINE SOFTWARE MARKET FOR OTHER END USERS: MAJOR PLAYERS AND OFFERINGS 211 TABLE 133 NUCLEAR MEDICINE SOFTWARE MARKET FOR OTHER END USERS, BY REGION, 2023–2030 (USD MILLION) 211 TABLE 134 NUCLEAR MEDICINE SOFTWARE MARKET, BY REGION, 2023–2030 (USD MILLION) 213 TABLE 135 NORTH AMERICA: MACROECONOMIC OUTLOOK 215 TABLE 136 NORTH AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 216 TABLE 137 NORTH AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE TYPE, 2023–2030 (USD MILLION) 216 TABLE 138 NORTH AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET, BY WORKFLOW, 2023–2030 (USD MILLION) 217 TABLE 139 NORTH AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET, BY INTEGRATION COMPLEXITY, 2023–2030 (USD MILLION) 217 TABLE 140 NORTH AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE LICENSING, 2023–2030 (USD MILLION) 217 TABLE 141 NORTH AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET, BY REVENUE MODEL, 2023–2030 (USD MILLION) 218 TABLE 142 NORTH AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 218 TABLE 143 NORTH AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 218 TABLE 144 NORTH AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 219 TABLE 145 NORTH AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 219 TABLE 146 NORTH AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET, BY TECHNOLOGY MATURITY, 2023–2030 (USD MILLION) 219 TABLE 147 NORTH AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET FOR UPCOMING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 220 TABLE 148 NORTH AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET FOR MATURE TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 220 TABLE 149 NORTH AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET, BY END USER, 2023–2030 (USD MILLION) 220 TABLE 150 NORTH AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023–2030 (USD MILLION) 221 TABLE 151 US: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE TYPE, 2023–2030 (USD MILLION) 222 TABLE 152 US: NUCLEAR MEDICINE SOFTWARE MARKET, BY WORKFLOW, 2023–2030 (USD MILLION) 222 TABLE 153 US: NUCLEAR MEDICINE SOFTWARE MARKET, BY INTEGRATION COMPLEXITY, 2023–2030 (USD MILLION) 223 TABLE 154 US: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE LICENSING, 2023–2030 (USD MILLION) 223 TABLE 155 US: NUCLEAR MEDICINE SOFTWARE MARKET, BY REVENUE MODEL, 2023–2030 (USD MILLION) 223 TABLE 156 US: NUCLEAR MEDICINE SOFTWARE MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 224 TABLE 157 US: NUCLEAR MEDICINE SOFTWARE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 224 TABLE 158 US: NUCLEAR MEDICINE SOFTWARE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 224 TABLE 159 US: NUCLEAR MEDICINE SOFTWARE MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 225 TABLE 160 US: NUCLEAR MEDICINE SOFTWARE MARKET, BY TECHNOLOGY MATURITY, 2023–2030 (USD MILLION) 225 TABLE 161 US: NUCLEAR MEDICINE SOFTWARE MARKET FOR UPCOMING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 225 TABLE 162 US: NUCLEAR MEDICINE SOFTWARE MARKET FOR MATURE TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 226 TABLE 163 US: NUCLEAR MEDICINE SOFTWARE MARKET, BY END USER, 2023–2030 (USD MILLION) 226 TABLE 164 US: NUCLEAR MEDICINE SOFTWARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023–2030 (USD MILLION) 226 TABLE 165 CANADA: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE TYPE, 2023–2030 (USD MILLION) 228 TABLE 166 CANADA: NUCLEAR MEDICINE SOFTWARE MARKET, BY WORKFLOW, 2023–2030 (USD MILLION) 228 TABLE 167 CANADA: NUCLEAR MEDICINE SOFTWARE MARKET, BY INTEGRATION COMPLEXITY, 2023–2030 (USD MILLION) 229 TABLE 168 CANADA: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE LICENSING, 2023–2030 (USD MILLION) 229 TABLE 169 CANADA: NUCLEAR MEDICINE SOFTWARE MARKET, BY REVENUE MODEL, 2023–2030 (USD MILLION) 229 TABLE 170 CANADA: NUCLEAR MEDICINE SOFTWARE MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 230 TABLE 171 CANADA: NUCLEAR MEDICINE SOFTWARE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 230 TABLE 172 CANADA: NUCLEAR MEDICINE SOFTWARE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 230 TABLE 173 CANADA: NUCLEAR MEDICINE SOFTWARE MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 231 TABLE 174 CANADA: NUCLEAR MEDICINE SOFTWARE MARKET, BY TECHNOLOGY MATURITY, 2023–2030 (USD MILLION) 231 TABLE 175 CANADA: NUCLEAR MEDICINE SOFTWARE MARKET FOR UPCOMING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 231 TABLE 176 CANADA: NUCLEAR MEDICINE SOFTWARE MARKET FOR MATURE TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 232 TABLE 177 CANADA: NUCLEAR MEDICINE SOFTWARE MARKET, BY END USER, 2023–2030 (USD MILLION) 232 TABLE 178 CANADA: NUCLEAR MEDICINE SOFTWARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023–2030 (USD MILLION) 232 TABLE 179 EUROPE: MACROECONOMIC OUTLOOK 234 TABLE 180 EUROPE: NUCLEAR MEDICINE SOFTWARE MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 234 TABLE 181 EUROPE: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE TYPE, 2023–2030 (USD MILLION) 235 TABLE 182 EUROPE: NUCLEAR MEDICINE SOFTWARE MARKET, BY WORKFLOW, 2023–2030 (USD MILLION) 235 TABLE 183 EUROPE: NUCLEAR MEDICINE SOFTWARE MARKET, BY INTEGRATION COMPLEXITY, 2023–2030 (USD MILLION) 236 TABLE 184 EUROPE: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE LICENSING, 2023–2030 (USD MILLION) 236 TABLE 185 EUROPE: NUCLEAR MEDICINE SOFTWARE MARKET, BY REVENUE MODEL, 2023–2030 (USD MILLION) 236 TABLE 186 EUROPE: NUCLEAR MEDICINE SOFTWARE MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 237 TABLE 187 EUROPE: NUCLEAR MEDICINE SOFTWARE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 237 TABLE 188 EUROPE: NUCLEAR MEDICINE SOFTWARE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 237 TABLE 189 EUROPE: NUCLEAR MEDICINE SOFTWARE MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 238 TABLE 190 EUROPE: NUCLEAR MEDICINE SOFTWARE MARKET, BY TECHNOLOGY MATURITY, 2023–2030 (USD MILLION) 238 TABLE 191 EUROPE: NUCLEAR MEDICINE SOFTWARE MARKET FOR UPCOMING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 238 TABLE 192 EUROPE: NUCLEAR MEDICINE SOFTWARE MARKET FOR MATURE TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 239 TABLE 193 EUROPE: NUCLEAR MEDICINE SOFTWARE MARKET, BY END USER, 2023–2030 (USD MILLION) 239 TABLE 194 EUROPE: NUCLEAR MEDICINE SOFTWARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023–2030 (USD MILLION) 239 TABLE 195 GERMANY: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE TYPE, 2023–2030 (USD MILLION) 241 TABLE 196 GERMANY: NUCLEAR MEDICINE SOFTWARE MARKET, BY WORKFLOW, 2023–2030 (USD MILLION) 241 TABLE 197 GERMANY: NUCLEAR MEDICINE SOFTWARE MARKET, BY INTEGRATION COMPLEXITY, 2023–2030 (USD MILLION) 242 TABLE 198 GERMANY: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE LICENSING, 2023–2030 (USD MILLION) 242 TABLE 199 GERMANY: NUCLEAR MEDICINE SOFTWARE MARKET, BY REVENUE MODEL, 2023–2030 (USD MILLION) 242 TABLE 200 GERMANY: NUCLEAR MEDICINE SOFTWARE MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 243 TABLE 201 GERMANY: NUCLEAR MEDICINE SOFTWARE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 243 TABLE 202 GERMANY: NUCLEAR MEDICINE SOFTWARE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 243 TABLE 203 GERMANY: NUCLEAR MEDICINE SOFTWARE MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 244 TABLE 204 GERMANY: NUCLEAR MEDICINE SOFTWARE MARKET, BY TECHNOLOGY MATURITY, 2023–2030 (USD MILLION) 244 TABLE 205 GERMANY: NUCLEAR MEDICINE SOFTWARE MARKET FOR UPCOMING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 244 TABLE 206 GERMANY: NUCLEAR MEDICINE SOFTWARE MARKET FOR MATURE TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 245 TABLE 207 GERMANY: NUCLEAR MEDICINE SOFTWARE MARKET, BY END USER, 2023–2030 (USD MILLION) 245 TABLE 208 GERMANY: NUCLEAR MEDICINE SOFTWARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023–2030 (USD MILLION) 245 TABLE 209 UK: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE TYPE, 2023–2030 (USD MILLION) 247 TABLE 210 UK: NUCLEAR MEDICINE SOFTWARE MARKET, BY WORKFLOW, 2023–2030 (USD MILLION) 247 TABLE 211 UK: NUCLEAR MEDICINE SOFTWARE MARKET, BY INTEGRATION COMPLEXITY, 2023–2030 (USD MILLION) 248 TABLE 212 UK: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE LICENSING, 2023–2030 (USD MILLION) 248 TABLE 213 UK: NUCLEAR MEDICINE SOFTWARE MARKET, BY REVENUE MODEL, 2023–2030 (USD MILLION) 248 TABLE 214 UK: NUCLEAR MEDICINE SOFTWARE MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 249 TABLE 215 UK: NUCLEAR MEDICINE SOFTWARE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 249 TABLE 216 UK: NUCLEAR MEDICINE SOFTWARE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 249 TABLE 217 UK: NUCLEAR MEDICINE SOFTWARE MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 250 TABLE 218 UK: NUCLEAR MEDICINE SOFTWARE MARKET, BY TECHNOLOGY MATURITY, 2023–2030 (USD MILLION) 250 TABLE 219 UK: NUCLEAR MEDICINE SOFTWARE MARKET FOR UPCOMING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 250 TABLE 220 UK: NUCLEAR MEDICINE SOFTWARE MARKET FOR MATURE TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 251 TABLE 221 UK: NUCLEAR MEDICINE SOFTWARE MARKET, BY END USER, 2023–2030 (USD MILLION) 251 TABLE 222 UK: NUCLEAR MEDICINE SOFTWARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023–2030 (USD MILLION) 251 TABLE 223 FRANCE: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE TYPE, 2023–2030 (USD MILLION) 253 TABLE 224 FRANCE: NUCLEAR MEDICINE SOFTWARE MARKET, BY WORKFLOW, 2023–2030 (USD MILLION) 253 TABLE 225 FRANCE: NUCLEAR MEDICINE SOFTWARE MARKET, BY INTEGRATION COMPLEXITY, 2023–2030 (USD MILLION) 254 TABLE 226 FRANCE: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE LICENSING, 2023–2030 (USD MILLION) 254 TABLE 227 FRANCE: NUCLEAR MEDICINE SOFTWARE MARKET, BY REVENUE MODEL, 2023–2030 (USD MILLION) 254 TABLE 228 FRANCE: NUCLEAR MEDICINE SOFTWARE MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 255 TABLE 229 FRANCE: NUCLEAR MEDICINE SOFTWARE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 255 TABLE 230 FRANCE: NUCLEAR MEDICINE SOFTWARE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 255 TABLE 231 FRANCE: NUCLEAR MEDICINE SOFTWARE MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 256 TABLE 232 FRANCE: NUCLEAR MEDICINE SOFTWARE MARKET, BY TECHNOLOGY MATURITY, 2023–2030 (USD MILLION) 256 TABLE 233 FRANCE: NUCLEAR MEDICINE SOFTWARE MARKET FOR UPCOMING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 256 TABLE 234 FRANCE: NUCLEAR MEDICINE SOFTWARE MARKET FOR MATURE TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 257 TABLE 235 FRANCE: NUCLEAR MEDICINE SOFTWARE MARKET, BY END USER, 2023–2030 (USD MILLION) 257 TABLE 236 FRANCE: NUCLEAR MEDICINE SOFTWARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023–2030 (USD MILLION) 257 TABLE 237 ITALY: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE TYPE, 2023–2030 (USD MILLION) 259 TABLE 238 ITALY: NUCLEAR MEDICINE SOFTWARE MARKET, BY WORKFLOW, 2023–2030 (USD MILLION) 259 TABLE 239 ITALY: NUCLEAR MEDICINE SOFTWARE MARKET, BY INTEGRATION COMPLEXITY, 2023–2030 (USD MILLION) 260 TABLE 240 ITALY: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE LICENSING, 2023–2030 (USD MILLION) 260 TABLE 241 ITALY: NUCLEAR MEDICINE SOFTWARE MARKET, BY REVENUE MODEL, 2023–2030 (USD MILLION) 260 TABLE 242 ITALY: NUCLEAR MEDICINE SOFTWARE MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 261 TABLE 243 ITALY: NUCLEAR MEDICINE SOFTWARE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 261 TABLE 244 ITALY: NUCLEAR MEDICINE SOFTWARE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 261 TABLE 245 ITALY: NUCLEAR MEDICINE SOFTWARE MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 262 TABLE 246 ITALY: NUCLEAR MEDICINE SOFTWARE MARKET, BY TECHNOLOGY MATURITY, 2023–2030 (USD MILLION) 262 TABLE 247 ITALY: NUCLEAR MEDICINE SOFTWARE MARKET FOR UPCOMING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 262 TABLE 248 ITALY: NUCLEAR MEDICINE SOFTWARE MARKET FOR MATURE TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 263 TABLE 249 ITALY: NUCLEAR MEDICINE SOFTWARE MARKET, BY END USER, 2023–2030 (USD MILLION) 263 TABLE 250 ITALY: NUCLEAR MEDICINE SOFTWARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023–2030 (USD MILLION) 263 TABLE 251 SPAIN: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE TYPE, 2023–2030 (USD MILLION) 265 TABLE 252 SPAIN: NUCLEAR MEDICINE SOFTWARE MARKET, BY WORKFLOW, 2023–2030 (USD MILLION) 265 TABLE 253 SPAIN: NUCLEAR MEDICINE SOFTWARE MARKET, BY INTEGRATION COMPLEXITY, 2023–2030 (USD MILLION) 266 TABLE 254 SPAIN: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE LICENSING, 2023–2030 (USD MILLION) 266 TABLE 255 SPAIN: NUCLEAR MEDICINE SOFTWARE MARKET, BY REVENUE MODEL, 2023–2030 (USD MILLION) 266 TABLE 256 SPAIN: NUCLEAR MEDICINE SOFTWARE MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 267 TABLE 257 SPAIN: NUCLEAR MEDICINE SOFTWARE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 267 TABLE 258 SPAIN: NUCLEAR MEDICINE SOFTWARE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 267 TABLE 259 SPAIN: NUCLEAR MEDICINE SOFTWARE MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 268 TABLE 260 SPAIN: NUCLEAR MEDICINE SOFTWARE MARKET, BY TECHNOLOGY MATURITY, 2023–2030 (USD MILLION) 268 TABLE 261 SPAIN: NUCLEAR MEDICINE SOFTWARE MARKET FOR UPCOMING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 268 TABLE 262 SPAIN: NUCLEAR MEDICINE SOFTWARE MARKET FOR MATURE TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 269 TABLE 263 SPAIN: NUCLEAR MEDICINE SOFTWARE MARKET, BY END USER, 2023–2030 (USD MILLION) 269 TABLE 264 SPAIN: NUCLEAR MEDICINE SOFTWARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023–2030 (USD MILLION) 269 TABLE 265 REST OF EUROPE: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE TYPE, 2023–2030 (USD MILLION) 271 TABLE 266 REST OF EUROPE: NUCLEAR MEDICINE SOFTWARE MARKET, BY WORKFLOW, 2023–2030 (USD MILLION) 271 TABLE 267 REST OF EUROPE: NUCLEAR MEDICINE SOFTWARE MARKET, BY INTEGRATION COMPLEXITY, 2023–2030 (USD MILLION) 272 TABLE 268 REST OF EUROPE: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE LICENSING, 2023–2030 (USD MILLION) 272 TABLE 269 REST OF EUROPE: NUCLEAR MEDICINE SOFTWARE MARKET, BY REVENUE MODEL, 2023–2030 (USD MILLION) 272 TABLE 270 REST OF EUROPE: NUCLEAR MEDICINE SOFTWARE MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 273 TABLE 271 REST OF EUROPE: NUCLEAR MEDICINE SOFTWARE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 273 TABLE 272 REST OF EUROPE: NUCLEAR MEDICINE SOFTWARE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 273 TABLE 273 REST OF EUROPE: NUCLEAR MEDICINE SOFTWARE MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 274 TABLE 274 REST OF EUROPE: NUCLEAR MEDICINE SOFTWARE MARKET, BY TECHNOLOGY MATURITY, 2023–2030 (USD MILLION) 274 TABLE 275 REST OF EUROPE: NUCLEAR MEDICINE SOFTWARE MARKET FOR UPCOMING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 274 TABLE 276 REST OF EUROPE: NUCLEAR MEDICINE SOFTWARE MARKET FOR MATURE TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 275 TABLE 277 REST OF EUROPE: NUCLEAR MEDICINE SOFTWARE MARKET, BY END USER, 2023–2030 (USD MILLION) 275 TABLE 278 REST OF EUROPE: NUCLEAR MEDICINE SOFTWARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023–2030 (USD MILLION) 275 TABLE 279 ASIA PACIFIC: MACROECONOMIC OUTLOOK 277 TABLE 280 ASIA PACIFIC: NUCLEAR MEDICINE SOFTWARE MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 279 TABLE 281 ASIA PACIFIC: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE TYPE, 2023–2030 (USD MILLION) 279 TABLE 282 ASIA PACIFIC: NUCLEAR MEDICINE SOFTWARE MARKET, BY WORKFLOW, 2023–2030 (USD MILLION) 280 TABLE 283 ASIA PACIFIC: NUCLEAR MEDICINE SOFTWARE MARKET, BY INTEGRATION COMPLEXITY, 2023–2030 (USD MILLION) 280 TABLE 284 ASIA PACIFIC: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE LICENSING, 2023–2030 (USD MILLION) 280 TABLE 285 ASIA PACIFIC: NUCLEAR MEDICINE SOFTWARE MARKET, BY REVENUE MODEL, 2023–2030 (USD MILLION) 281 TABLE 286 ASIA PACIFIC: NUCLEAR MEDICINE SOFTWARE MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 281 TABLE 287 ASIA PACIFIC: NUCLEAR MEDICINE SOFTWARE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 281 TABLE 288 ASIA PACIFIC: NUCLEAR MEDICINE SOFTWARE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 282 TABLE 289 ASIA PACIFIC: NUCLEAR MEDICINE SOFTWARE MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 282 TABLE 290 ASIA PACIFIC: NUCLEAR MEDICINE SOFTWARE MARKET, BY TECHNOLOGY MATURITY, 2023–2030 (USD MILLION) 282 TABLE 291 ASIA PACIFIC: NUCLEAR MEDICINE SOFTWARE MARKET FOR UPCOMING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 283 TABLE 292 ASIA PACIFIC: NUCLEAR MEDICINE SOFTWARE MARKET FOR MATURE TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 283 TABLE 293 ASIA PACIFIC: NUCLEAR MEDICINE SOFTWARE MARKET, BY END USER, 2023–2030 (USD MILLION) 283 TABLE 294 ASIA PACIFIC: NUCLEAR MEDICINE SOFTWARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023–2030 (USD MILLION) 284 TABLE 295 JAPAN: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE TYPE, 2023–2030 (USD MILLION) 285 TABLE 296 JAPAN: NUCLEAR MEDICINE SOFTWARE MARKET, BY WORKFLOW, 2023–2030 (USD MILLION) 285 TABLE 297 JAPAN: NUCLEAR MEDICINE SOFTWARE MARKET, BY INTEGRATION COMPLEXITY, 2023–2030 (USD MILLION) 286 TABLE 298 JAPAN: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE LICENSING, 2023–2030 (USD MILLION) 286 TABLE 299 JAPAN: NUCLEAR MEDICINE SOFTWARE MARKET, BY REVENUE MODEL, 2023–2030 (USD MILLION) 286 TABLE 300 JAPAN: NUCLEAR MEDICINE SOFTWARE MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 287 TABLE 301 JAPAN: NUCLEAR MEDICINE SOFTWARE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 287 TABLE 302 JAPAN: NUCLEAR MEDICINE SOFTWARE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 287 TABLE 303 JAPAN: NUCLEAR MEDICINE SOFTWARE MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 288 TABLE 304 JAPAN: NUCLEAR MEDICINE SOFTWARE MARKET, BY TECHNOLOGY MATURITY, 2023–2030 (USD MILLION) 288 TABLE 305 JAPAN: NUCLEAR MEDICINE SOFTWARE MARKET FOR UPCOMING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 288 TABLE 306 JAPAN: NUCLEAR MEDICINE SOFTWARE MARKET FOR MATURE TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 289 TABLE 307 JAPAN: NUCLEAR MEDICINE SOFTWARE MARKET, BY END USER, 2023–2030 (USD MILLION) 289 TABLE 308 JAPAN: NUCLEAR MEDICINE SOFTWARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023–2030 (USD MILLION) 289 TABLE 309 CHINA: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE TYPE, 2023–2030 (USD MILLION) 291 TABLE 310 CHINA: NUCLEAR MEDICINE SOFTWARE MARKET, BY WORKFLOW, 2023–2030 (USD MILLION) 291 TABLE 311 CHINA: NUCLEAR MEDICINE SOFTWARE MARKET, BY INTEGRATION COMPLEXITY, 2023–2030 (USD MILLION) 292 TABLE 312 CHINA: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE LICENSING, 2023–2030 (USD MILLION) 292 TABLE 313 CHINA: NUCLEAR MEDICINE SOFTWARE MARKET, BY REVENUE MODEL, 2023–2030 (USD MILLION) 292 TABLE 314 CHINA: NUCLEAR MEDICINE SOFTWARE MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 293 TABLE 315 CHINA: NUCLEAR MEDICINE SOFTWARE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 293 TABLE 316 CHINA: NUCLEAR MEDICINE SOFTWARE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 293 TABLE 317 CHINA: NUCLEAR MEDICINE SOFTWARE MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 294 TABLE 318 CHINA: NUCLEAR MEDICINE SOFTWARE MARKET, BY TECHNOLOGY MATURITY, 2023–2030 (USD MILLION) 294 TABLE 319 CHINA: NUCLEAR MEDICINE SOFTWARE MARKET FOR UPCOMING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 294 TABLE 320 CHINA: NUCLEAR MEDICINE SOFTWARE MARKET FOR MATURE TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 295 TABLE 321 CHINA: NUCLEAR MEDICINE SOFTWARE MARKET, BY END USER, 2023–2030 (USD MILLION) 295 TABLE 322 CHINA: NUCLEAR MEDICINE SOFTWARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023–2030 (USD MILLION) 295 TABLE 323 INDIA: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE TYPE, 2023–2030 (USD MILLION) 297 TABLE 324 INDIA: NUCLEAR MEDICINE SOFTWARE MARKET, BY WORKFLOW, 2023–2030 (USD MILLION) 297 TABLE 325 INDIA: NUCLEAR MEDICINE SOFTWARE MARKET, BY INTEGRATION COMPLEXITY, 2023–2030 (USD MILLION) 298 TABLE 326 INDIA: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE LICENSING, 2023–2030 (USD MILLION) 298 TABLE 327 INDIA: NUCLEAR MEDICINE SOFTWARE MARKET, BY REVENUE MODEL, 2023–2030 (USD MILLION) 298 TABLE 328 INDIA: NUCLEAR MEDICINE SOFTWARE MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 299 TABLE 329 INDIA: NUCLEAR MEDICINE SOFTWARE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 299 TABLE 330 INDIA: NUCLEAR MEDICINE SOFTWARE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 299 TABLE 331 INDIA: NUCLEAR MEDICINE SOFTWARE MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 300 TABLE 332 INDIA: NUCLEAR MEDICINE SOFTWARE MARKET, BY TECHNOLOGY MATURITY, 2023–2030 (USD MILLION) 300 TABLE 333 INDIA: NUCLEAR MEDICINE SOFTWARE MARKET FOR UPCOMING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 300 TABLE 334 INDIA: NUCLEAR MEDICINE SOFTWARE MARKET FOR MATURE TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 301 TABLE 335 INDIA: NUCLEAR MEDICINE SOFTWARE MARKET, BY END USER, 2023–2030 (USD MILLION) 301 TABLE 336 INDIA: NUCLEAR MEDICINE SOFTWARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023–2030 (USD MILLION) 301 TABLE 337 REST OF ASIA PACIFIC: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE TYPE, 2023–2030 (USD MILLION) 302 TABLE 338 REST OF ASIA PACIFIC: NUCLEAR MEDICINE SOFTWARE MARKET, BY WORKFLOW, 2023–2030 (USD MILLION) 303 TABLE 339 REST OF ASIA PACIFIC: NUCLEAR MEDICINE SOFTWARE MARKET, BY INTEGRATION COMPLEXITY, 2023–2030 (USD MILLION) 303 TABLE 340 REST OF ASIA PACIFIC: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE LICENSING, 2023–2030 (USD MILLION) 303 TABLE 341 REST OF ASIA PACIFIC: NUCLEAR MEDICINE SOFTWARE MARKET, BY REVENUE MODEL, 2023–2030 (USD MILLION) 304 TABLE 342 REST OF ASIA PACIFIC: NUCLEAR MEDICINE SOFTWARE MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 304 TABLE 343 REST OF ASIA PACIFIC: NUCLEAR MEDICINE SOFTWARE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 304 TABLE 344 REST OF ASIA PACIFIC: NUCLEAR MEDICINE SOFTWARE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 305 TABLE 345 REST OF ASIA PACIFIC: NUCLEAR MEDICINE SOFTWARE MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 305 TABLE 346 REST OF ASIA PACIFIC: NUCLEAR MEDICINE SOFTWARE MARKET, BY TECHNOLOGY MATURITY, 2023–2030 (USD MILLION) 305 TABLE 347 REST OF ASIA PACIFIC: NUCLEAR MEDICINE SOFTWARE MARKET FOR UPCOMING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 306 TABLE 348 REST OF ASIA PACIFIC: NUCLEAR MEDICINE SOFTWARE MARKET FOR MATURE TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 306 TABLE 349 REST OF ASIA PACIFIC: NUCLEAR MEDICINE SOFTWARE MARKET, BY END USER, 2023–2030 (USD MILLION) 306 TABLE 350 REST OF ASIA PACIFIC: NUCLEAR MEDICINE SOFTWARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023–2030 (USD MILLION) 307 TABLE 351 LATIN AMERICA: MACROECONOMIC OUTLOOK 308 TABLE 352 LATIN AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 308 TABLE 353 LATIN AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE TYPE, 2023–2030 (USD MILLION) 309 TABLE 354 LATIN AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET, BY WORKFLOW, 2023–2030 (USD MILLION) 309 TABLE 355 LATIN AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET, BY INTEGRATION COMPLEXITY, 2023–2030 (USD MILLION) 310 TABLE 356 LATIN AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE LICENSING, 2023–2030 (USD MILLION) 310 TABLE 357 LATIN AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET, BY REVENUE MODEL, 2023–2030 (USD MILLION) 310 TABLE 358 LATIN AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 311 TABLE 359 LATIN AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 311 TABLE 360 LATIN AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 311 TABLE 361 LATIN AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 312 TABLE 362 LATIN AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET, BY TECHNOLOGY MATURITY, 2023–2030 (USD MILLION) 312 TABLE 363 LATIN AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET FOR UPCOMING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 312 TABLE 364 LATIN AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET FOR MATURE TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 313 TABLE 365 LATIN AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET, BY END USER, 2023–2030 (USD MILLION) 313 TABLE 366 LATIN AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023–2030 (USD MILLION) 313 TABLE 367 BRAZIL: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE TYPE, 2023–2030 (USD MILLION) 315 TABLE 368 BRAZIL: NUCLEAR MEDICINE SOFTWARE MARKET, BY WORKFLOW, 2023–2030 (USD MILLION) 315 TABLE 369 BRAZIL: NUCLEAR MEDICINE SOFTWARE MARKET, BY INTEGRATION COMPLEXITY, 2023–2030 (USD MILLION) 316 TABLE 370 BRAZIL: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE LICENSING, 2023–2030 (USD MILLION) 316 TABLE 371 BRAZIL: NUCLEAR MEDICINE SOFTWARE MARKET, BY REVENUE MODEL, 2023–2030 (USD MILLION) 316 TABLE 372 BRAZIL: NUCLEAR MEDICINE SOFTWARE MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 317 TABLE 373 BRAZIL: NUCLEAR MEDICINE SOFTWARE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 317 TABLE 374 BRAZIL: NUCLEAR MEDICINE SOFTWARE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 317 TABLE 375 BRAZIL: NUCLEAR MEDICINE SOFTWARE MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 318 TABLE 376 BRAZIL: NUCLEAR MEDICINE SOFTWARE MARKET, BY TECHNOLOGY MATURITY, 2023–2030 (USD MILLION) 318 TABLE 377 BRAZIL: NUCLEAR MEDICINE SOFTWARE MARKET FOR UPCOMING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 318 TABLE 378 BRAZIL: NUCLEAR MEDICINE SOFTWARE MARKET FOR MATURE TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 319 TABLE 379 BRAZIL: NUCLEAR MEDICINE SOFTWARE MARKET, BY END USER, 2023–2030 (USD MILLION) 319 TABLE 380 BRAZIL: NUCLEAR MEDICINE SOFTWARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023–2030 (USD MILLION) 319 TABLE 381 MEXICO: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE TYPE, 2023–2030 (USD MILLION) 321 TABLE 382 MEXICO: NUCLEAR MEDICINE SOFTWARE MARKET, BY WORKFLOW, 2023–2030 (USD MILLION) 321 TABLE 383 MEXICO: NUCLEAR MEDICINE SOFTWARE MARKET, BY INTEGRATION COMPLEXITY, 2023–2030 (USD MILLION) 322 TABLE 384 MEXICO: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE LICENSING, 2023–2030 (USD MILLION) 322 TABLE 385 MEXICO: NUCLEAR MEDICINE SOFTWARE MARKET, BY REVENUE MODEL, 2023–2030 (USD MILLION) 322 TABLE 386 MEXICO: NUCLEAR MEDICINE SOFTWARE MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 323 TABLE 387 MEXICO: NUCLEAR MEDICINE SOFTWARE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 323 TABLE 388 MEXICO: NUCLEAR MEDICINE SOFTWARE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 323 TABLE 389 MEXICO: NUCLEAR MEDICINE SOFTWARE MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 324 TABLE 390 MEXICO: NUCLEAR MEDICINE SOFTWARE MARKET, BY TECHNOLOGY MATURITY, 2023–2030 (USD MILLION) 324 TABLE 391 MEXICO: NUCLEAR MEDICINE SOFTWARE MARKET FOR UPCOMING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 324 TABLE 392 MEXICO: NUCLEAR MEDICINE SOFTWARE MARKET FOR MATURE TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 325 TABLE 393 MEXICO: NUCLEAR MEDICINE SOFTWARE MARKET, BY END USER, 2023–2030 (USD MILLION) 325 TABLE 394 MEXICO: NUCLEAR MEDICINE SOFTWARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023–2030 (USD MILLION) 325 TABLE 395 REST OF LATIN AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE TYPE, 2023–2030 (USD MILLION) 326 TABLE 396 REST OF LATIN AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET, BY WORKFLOW, 2023–2030 (USD MILLION) 327 TABLE 397 REST OF LATIN AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET, BY INTEGRATION COMPLEXITY, 2023–2030 (USD MILLION) 327 TABLE 398 REST OF LATIN AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE LICENSING, 2023–2030 (USD MILLION) 327 TABLE 399 REST OF LATIN AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET, BY REVENUE MODEL, 2023–2030 (USD MILLION) 328 TABLE 400 REST OF LATIN AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 328 TABLE 401 REST OF LATIN AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 328 TABLE 402 REST OF LATIN AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 329 TABLE 403 REST OF LATIN AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 329 TABLE 404 REST OF LATIN AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET, BY TECHNOLOGY MATURITY, 2023–2030 (USD MILLION) 329 TABLE 405 REST OF LATIN AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET FOR UPCOMING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 330 TABLE 406 REST OF LATIN AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET FOR MATURE TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 330 TABLE 407 REST OF LATIN AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET, BY END USER, 2023–2030 (USD MILLION) 330 TABLE 408 REST OF LATIN AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023–2030 (USD MILLION) 331 TABLE 409 MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK 332 TABLE 410 MIDDLE EAST & AFRICA: NUCLEAR MEDICINE SOFTWARE MARKET, BY REGION, 2023–2030 (USD MILLION) 332 TABLE 411 MIDDLE EAST & AFRICA: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE TYPE, 2023–2030 (USD MILLION) 333 TABLE 412 MIDDLE EAST & AFRICA: NUCLEAR MEDICINE SOFTWARE MARKET, BY WORKFLOW, 2023–2030 (USD MILLION) 333 TABLE 413 MIDDLE EAST & AFRICA: NUCLEAR MEDICINE SOFTWARE MARKET, BY INTEGRATION COMPLEXITY, 2023–2030 (USD MILLION) 334 TABLE 414 MIDDLE EAST & AFRICA: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE LICENSING, 2023–2030 (USD MILLION) 334 TABLE 415 MIDDLE EAST & AFRICA: NUCLEAR MEDICINE SOFTWARE MARKET, BY REVENUE MODEL, 2023–2030 (USD MILLION) 334 TABLE 416 MIDDLE EAST & AFRICA: NUCLEAR MEDICINE SOFTWARE MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 335 TABLE 417 MIDDLE EAST & AFRICA: NUCLEAR MEDICINE SOFTWARE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 335 TABLE 418 MIDDLE EAST & AFRICA: NUCLEAR MEDICINE SOFTWARE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 335 TABLE 419 MIDDLE EAST & AFRICA: NUCLEAR MEDICINE SOFTWARE MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 336 TABLE 420 MIDDLE EAST & AFRICA: NUCLEAR MEDICINE SOFTWARE MARKET, BY TECHNOLOGY MATURITY, 2023–2030 (USD MILLION) 336 TABLE 421 MIDDLE EAST & AFRICA: NUCLEAR MEDICINE SOFTWARE MARKET FOR UPCOMING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 336 TABLE 422 MIDDLE EAST & AFRICA: NUCLEAR MEDICINE SOFTWARE MARKET FOR MATURE TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 337 TABLE 423 MIDDLE EAST & AFRICA: NUCLEAR MEDICINE SOFTWARE MARKET, BY END USER, 2023–2030 (USD MILLION) 337 TABLE 424 MIDDLE EAST & AFRICA: NUCLEAR MEDICINE SOFTWARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023–2030 (USD MILLION) 337 TABLE 425 GCC COUNTRIES: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE TYPE, 2023–2030 (USD MILLION) 339 TABLE 426 GCC COUNTRIES: NUCLEAR MEDICINE SOFTWARE MARKET, BY WORKFLOW, 2023–2030 (USD MILLION) 339 TABLE 427 GCC COUNTRIES: NUCLEAR MEDICINE SOFTWARE MARKET, BY INTEGRATION COMPLEXITY, 2023–2030 (USD MILLION) 340 TABLE 428 GCC COUNTRIES: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE LICENSING, 2023–2030 (USD MILLION) 340 TABLE 429 GCC COUNTRIES: NUCLEAR MEDICINE SOFTWARE MARKET, BY REVENUE MODEL, 2023–2030 (USD MILLION) 340 TABLE 430 GCC COUNTRIES: NUCLEAR MEDICINE SOFTWARE MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 341 TABLE 431 GCC COUNTRIES: NUCLEAR MEDICINE SOFTWARE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 341 TABLE 432 GCC COUNTRIES: NUCLEAR MEDICINE SOFTWARE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 341 TABLE 433 GCC COUNTRIES: NUCLEAR MEDICINE SOFTWARE MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 342 TABLE 434 GCC COUNTRIES: NUCLEAR MEDICINE SOFTWARE MARKET, BY TECHNOLOGY MATURITY, 2023–2030 (USD MILLION) 342 TABLE 435 GCC COUNTRIES: NUCLEAR MEDICINE SOFTWARE MARKET FOR UPCOMING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 342 TABLE 436 GCC COUNTRIES: NUCLEAR MEDICINE SOFTWARE MARKET FOR MATURE TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 343 TABLE 437 GCC COUNTRIES: NUCLEAR MEDICINE SOFTWARE MARKET, BY END USER, 2023–2030 (USD MILLION) 343 TABLE 438 GCC COUNTRIES: NUCLEAR MEDICINE SOFTWARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023–2030 (USD MILLION) 343 TABLE 439 REST OF MIDDLE EAST & AFRICA: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE TYPE, 2023–2030 (USD MILLION) 345 TABLE 440 REST OF MIDDLE EAST & AFRICA: NUCLEAR MEDICINE SOFTWARE MARKET, BY WORKFLOW, 2023–2030 (USD MILLION) 345 TABLE 441 REST OF MIDDLE EAST & AFRICA: NUCLEAR MEDICINE SOFTWARE MARKET, BY INTEGRATION COMPLEXITY, 2023–2030 (USD MILLION) 346 TABLE 442 REST OF MIDDLE EAST & AFRICA: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE LICENSING, 2023–2030 (USD MILLION) 346 TABLE 443 REST OF MIDDLE EAST & AFRICA: NUCLEAR MEDICINE SOFTWARE MARKET, BY REVENUE MODEL, 2023–2030 (USD MILLION) 346 TABLE 444 REST OF MIDDLE EAST & AFRICA: NUCLEAR MEDICINE SOFTWARE MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 347 TABLE 445 REST OF MIDDLE EAST & AFRICA: NUCLEAR MEDICINE SOFTWARE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 347 TABLE 446 REST OF MIDDLE EAST & AFRICA: NUCLEAR MEDICINE SOFTWARE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 347 TABLE 447 REST OF MIDDLE EAST & AFRICA: NUCLEAR MEDICINE SOFTWARE MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 348 TABLE 448 REST OF MIDDLE EAST & AFRICA: NUCLEAR MEDICINE SOFTWARE MARKET, BY TECHNOLOGY MATURITY, 2023–2030 (USD MILLION) 348 TABLE 449 REST OF MIDDLE EAST & AFRICA: NUCLEAR MEDICINE SOFTWARE MARKET FOR UPCOMING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 348 TABLE 450 REST OF MIDDLE EAST & AFRICA: NUCLEAR MEDICINE SOFTWARE MARKET FOR MATURE TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 349 TABLE 451 REST OF MIDDLE EAST & AFRICA: NUCLEAR MEDICINE SOFTWARE MARKET, BY END USER, 2023–2030 (USD MILLION) 349 TABLE 452 REST OF MIDDLE EAST & AFRICA: NUCLEAR MEDICINE SOFTWARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023–2030 (USD MILLION) 349 TABLE 453 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN NULEAR MEDICINE SOFTWARE MARKET, JANUARY 2022–JUNE 2025 351 TABLE 454 NUCLEAR MEDICINE SOFTWARE MARKET: DEGREE OF COMPETITION 355 TABLE 455 PET SOFTWARE MARKET: DEGREE OF COMPETITION 358 TABLE 456 SPECT SOFTWARE MARKET: DEGREE OF COMPETITION 360 TABLE 457 NUCLEAR MEDICINE SOFTWARE MARKET: REGION FOOTPRINT 366 TABLE 458 NUCLEAR MEDICINE SOFTWARE MARKET: SOFTWARE TYPE FOOTPRINT 367 TABLE 459 NUCLEAR MEDICINE SOFTWARE MARKET: WORKFLOW FOOTPRINT 368 TABLE 460 NUCLEAR MEDICINE SOFTWARE MARKET: INTEGRATION COMPLEXITY FOOTPRINT 369 TABLE 461 NUCLEAR MEDICINE SOFTWARE MARKET: APPLICATION FOOTPRINT 370 TABLE 462 NUCLEAR MEDICINE SOFTWARE MARKET: THERAPEUTIC AREA FOOTPRINT 371 TABLE 463 NUCLEAR MEDICINE SOFTWARE MARKET: END-USER FOOTPRINT 372 TABLE 464 NUCLEAR MEDICINE SOFTWARE MARKET: DETAILED LIST OF KEY STARTUP/SME PLAYERS 375 TABLE 465 NUCLEAR MEDICINE SOFTWARE MARKET: COMPETITIVE BENCHMARKING OF SMES/STARTUPS, BY REGION 375 TABLE 466 NUCLEAR MEDICINE SOFTWARE MARKET: COMPETITIVE BENCHMARKING OF SMES/STARTUPS, BY SOFTWARE TYPE 376 TABLE 467 NUCLEAR MEDICINE SOFTWARE MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–MAY 2025 377 TABLE 468 NUCLEAR MEDICINE SOFTWARE MARKET: DEALS, JANUARY 2022–MAY 2025 378 TABLE 469 NUCLEAR MEDICINE SOFTWARE MARKET: EXPANSIONS, JANUARY 2022–MAY 2025 380 TABLE 470 NUCLEAR MEDICINE SOFTWARE MARKET: OTHER DEVELOPMENTS, JANUARY 2022–MAY 2025 380 TABLE 471 GE HEALTHCARE: COMPANY OVERVIEW 381 TABLE 472 GE HEALTHCARE: PRODUCTS & SERVICES OFFERED 382 TABLE 473 GE HEALTHCARE: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–MAY 2025 CHECK 384 TABLE 474 GE HEALTHCARE: DEALS, JANUARY 2022–MAY 2025 384 TABLE 475 GE HEALTHCARE: EXPANSIONS, JANUARY 2022–MAY 2025 387 TABLE 476 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW 389 TABLE 477 SIEMENS HEALTHINEERS AG: PRODUCTS & SERVICES OFFERED 390 TABLE 478 SIEMENS HEALTHINEERS AG: PRODUCT LAUNCHES, JANUARY 2022–MAY 2025 392 TABLE 479 SIEMENS HEALTHINEERS AG: DEALS, JANUARY 2022–MAY 2025 393 TABLE 480 KONINKLIJKE PHILIPS N.V.: COMPANY OVERVIEW 395 TABLE 481 KONINKLIJKE PHILIPS N.V.: PRODUCTS & SERVICES OFFERED 396 TABLE 482 KONINKLIJKE PHILIPS N.V.: PRODUCT LAUNCHES, JANUARY 2022–MAY 2025 397 TABLE 483 LANTHEUS: COMPANY OVERVIEW 399 TABLE 484 LANTHEUS: PRODUCTS & SERVICES OFFERED 400 TABLE 485 LANTHEUS: DEALS, JANUARY 2022–MAY 2025 401 TABLE 486 LANTHEUS: OTHER DEVELOPMENTS, JANUARY 2022–MAY 2025 401 TABLE 487 CANON MEDICAL SYSTEMS CORPORATION: COMPANY OVERVIEW 404 TABLE 488 CANON MEDICAL SYSTEMS CORPORATION: PRODUCTS & SERVICES OFFERED 405 TABLE 489 CANON MEDICAL SYSTEMS CORPORATION: DEALS, JANUARY 2022–MAY 2025 406 TABLE 490 MIRION TECHNOLOGIES, INC.: COMPANY OVERVIEW 408 TABLE 491 MIRION TECHNOLOGIES, INC.: PRODUCTS & SERVICES OFFERED 409 TABLE 492 MIRION TECHNOLOGIES, INC.: PRODUCT LAUNCHES, JANUARY 2022–MAY 2025 411 TABLE 493 MIRION TECHNOLOGIES, INC.: DEALS, JANUARY 2022–MAY 2025 411 TABLE 494 BRAINLAB AG: COMPANY OVERVIEW 413 TABLE 495 BRAINLAB AG: PRODUCTS & SERVICES OFFERED 413 TABLE 496 BRAINLAB AG: PRODUCT APPROVALS, JANUARY 2022–MAY 2025 414 TABLE 497 MIRADA MEDICAL LIMITED: COMPANY OVERVIEW 415 TABLE 498 MIRADA MEDICAL LIMITED: PRODUCTS & SERVICES OFFERED 415 TABLE 499 MIRADA MEDICAL LIMITED: PRODUCT APPROVALS, JANUARY 2022–MAY 2025 416 TABLE 500 MIRADA MEDICAL LIMITED: DEALS, JANUARY 2022–MAY 2025 416 TABLE 501 DOSISOFT SA: COMPANY OVERVIEW 418 TABLE 502 DOSISOFT SA: PRODUCTS & SERVICES OFFERED 418 TABLE 503 DOSISOFT SA: PRODUCT APPROVALS, JANUARY 2022–MAY 2025 419 TABLE 504 DOSISOFT SA: DEALS, JANUARY 2022–MAY 2025 419 TABLE 505 BRACCO GROUP: COMPANY OVERVIEW 420 TABLE 506 BRACCO GROUP: PRODUCTS & SERVICES OFFERED 421 TABLE 507 BRACCO GROUP: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–MAY 2025 421 TABLE 508 HERMES MEDICAL SOLUTIONS: COMPANY OVERVIEW 422 TABLE 509 HERMES MEDICAL SOLUTIONS: PRODUCTS & SERVICES OFFERED 423 TABLE 510 HERMES MEDICAL SOLUTIONS: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–MAY 2025 424 TABLE 511 HERMES MEDICAL SOLUTIONS: DEALS, JANUARY 2022–MAY 2025 425 TABLE 512 INVIA, LLC: COMPANY OVERVIEW 426 TABLE 513 INVIA, LLC: PRODUCTS & SERVICES OFFERED 426 TABLE 514 INVIA, LLC: PRODUCT LAUNCHES, JANUARY 2022–MAY 2025 427 TABLE 515 INVIA, LLC: DEALS, JANUARY 2022–MAY 2025 427 TABLE 516 MEDISO LTD.: COMPANY OVERVIEW 428 TABLE 517 MEDISO LTD.: PRODUCTS & SERVICES OFFERED 429 TABLE 518 MEDISO LTD.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–MAY 2025 430 TABLE 519 LABLOGIC SYSTEMS LTD.: COMPANY OVERVIEW 431 TABLE 520 LABLOGIC SYSTEMS LTD.: PRODUCTS & SERVICES OFFERED 432 TABLE 521 LABLOGIC SYSTEMS LTD.: PRODUCT APPROVALS, JANUARY 2022–MAY 2025 433 TABLE 522 COMECER S.P.A.: COMPANY OVERVIEW 434 TABLE 523 COMECER S.P.A.: PRODUCTS & SERVICES OFFERED 435 TABLE 524 COMECER S.P.A.: PRODUCT UPDTAES, JANUARY 2022–MAY 2025 436 TABLE 525 COMECER S.P.A.: DEALS, JANUARY 2022–MAY 2025 436 TABLE 526 RAYSEARCH LABORATORIES: COMPANY OVERVIEW 437 TABLE 527 RAYSEARCH LABORATORIES: PRODUCTS & SERVICES OFFERED 438 TABLE 528 RAYSEARCH LABORATORIES: PRODUCT LAUNCHES, JANUARY 2022–MAY 2025 439 TABLE 529 ULTRASPECT INC.: COMPANY OVERVIEW 440 TABLE 530 ULTRASPECT INC.: PRODUCTS & SERVICES OFFERED 441 TABLE 531 SECTRA AB: COMPANY OVERVIEW 442 TABLE 532 SECTRA AB: PRODUCTS & SERVICES OFFERED 443 TABLE 533 SECTRA AB: PRODUCT LAUNCHES, JANUARY 2022–MAY 2025 444 TABLE 534 SECTRA AB: DEALS, JANUARY 2022–MAY 2025 444 TABLE 535 AGFA-GEVAERT GROUP: COMPANY OVERVIEW 445 TABLE 536 AGFA-GEVAERT GROUP: PRODUCTS & SERVICES OFFERED 446 TABLE 537 PERCEPTIVE: COMPANY OVERVIEW 447 TABLE 538 PERCEPTIVE: PRODUCTS & SERVICES OFFERED 447 TABLE 539 PERCEPTIVE: PRODUCT LAUNCHES, JANUARY 2022–MAY 2025 448 TABLE 540 PERCEPTIVE: DEALS, JANUARY 2022–MAY 2025 448 FIGURE 1 NUCLEAR MEDICINE SOFTWARE MARKET SEGMENTATION & REGIONAL SCOPE 43 FIGURE 2 RESEARCH DESIGN 47 FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 50 FIGURE 4 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 52 FIGURE 5 BOTTOM-UP APPROACH 53 FIGURE 6 TOP-DOWN APPROACH 54 FIGURE 7 CAGR PROJECTIONS FROM ANALYSIS OF MARKET DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF NUCLEAR MEDICINE SOFTWARE INDUSTRY 55 FIGURE 8 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 55 FIGURE 9 DATA TRIANGULATION METHODOLOGY 57 FIGURE 10 NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE TYPE, 2025 VS. 2030 (USD MILLION) 59 FIGURE 11 NUCLEAR MEDICINE SOFTWARE MARKET, BY WORKFLOW, 2025 VS. 2030 (USD MILLION) 60 FIGURE 12 NUCLEAR MEDICINE SOFTWARE MARKET, BY INTEGRATION COMPLEXITY, 2025 VS. 2030 (USD MILLION) 60 FIGURE 13 NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE LICENSING, 2025 VS. 2030 (USD MILLION) 61 FIGURE 14 NUCLEAR MEDICINE SOFTWARE MARKET, BY REVENUE MODEL, 2025 VS. 2030 (USD MILLION) 61 FIGURE 15 NUCLEAR MEDICINE SOFTWARE MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION) 62 FIGURE 16 NUCLEAR MEDICINE SOFTWARE MARKET, BY THERAPEUTIC AREA, 2025 VS. 2030 (USD MILLION) 62 FIGURE 17 NUCLEAR MEDICINE SOFTWARE MARKET, BY TECHNOLOGY MATURITY, 2025 VS. 2030 (USD MILLION) 63 FIGURE 18 NUCLEAR MEDICINE SOFTWARE MARKET, BY END USER, 2025 VS. 2030 (USD MILLION) 63 FIGURE 19 NUCLEAR MEDICINE SOFTWARE MARKET: REGIONAL SNAPSHOT 64 FIGURE 20 GROWING ADOPTION OF ADVANCED IMAGING MODALITIES, ENHANCED INTEROPERABILITY, AND EXPANSION OF REMOTE ACCESS TO DRIVE MARKET GROWTH 66 FIGURE 21 INTEGRATED SOLUTIONS SEGMENT AND JAPAN TO COMMAND LARGEST SHARES OF ASIA PACIFIC MARKET IN 2024 67 FIGURE 22 MARKET IN CHINA TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD 68 FIGURE 23 ASIA PACIFIC TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD 68 FIGURE 24 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH RATES DURING FORECAST PERIOD 69 FIGURE 25 MARKET DYNAMICS: NUCLEAR MEDICINE SOFTWARE MARKET 70 FIGURE 26 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 77 FIGURE 27 NUCLEAR MEDICINE SOFTWARE MARKET: ECOSYSTEM ANALYSIS 80 FIGURE 28 NUCLEAR MEDICINE SOFTWARE MARKET: SUPPLY CHAIN ANALYSIS 83 FIGURE 29 NUCLEAR MEDICINE SOFTWARE: PORTER’S FIVE FORCES ANALYSIS 94 FIGURE 30 JURISDICTION AND TOP APPLICANT ANALYSIS OF NUCLEAR MEDICINE SOFTWARE SOLUTIONS 96 FIGURE 31 TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTIONS) FOR NUCLEAR MEDICINE SOFTWARE MARKET (JANUARY 2015 TO MAY 2025) 97 FIGURE 32 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS 98 FIGURE 33 KEY BUYING CRITERIA FOR END USERS 99 FIGURE 34 INVESTOR DEALS AND FUNDING IN NUCLEAR MEDICINE SOFTWARE MARKET 105 FIGURE 35 MARKET POTENTIAL OF AI/GENERATIVE AI ON NUCLEAR MEDICINE SOFTWARE SOLUTIONS ACROSS INDUSTRIES 107 FIGURE 36 PRICE IMPACT ANALYSIS 115 FIGURE 37 NORTH AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET SNAPSHOT 215 FIGURE 38 ASIA PACIFIC: NUCLEAR MEDICINE SOFTWARE MARKET SNAPSHOT 278 FIGURE 39 REVENUE ANALYSIS OF KEY PLAYERS IN NUCLEAR MEDICINE SOFTWARE MARKET, 2020–2024 354 FIGURE 40 MARKET SHARE ANALYSIS OF KEY PLAYERS IN NUCLEAR MEDICINE SOFTWARE MARKET, 2024 355 FIGURE 41 MARKET SHARE ANALYSIS OF KEY PLAYERS IN PET SOFTWARE MARKET, 2024 357 FIGURE 42 MARKET SHARE ANALYSIS OF KEY PLAYERS IN SPECT SOFTWARE MARKET, 2024 359 FIGURE 43 NUCLEAR MEDICINE SOFTWARE MARKET: BRAND/SOFTWARE COMPARITIVE ANALYSIS 361 FIGURE 44 EV/EBITDA OF KEY VENDORS 362 FIGURE 45 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA 362 FIGURE 46 NUCLEAR MEDICINE SOFTWARE MARKET: KEY PLAYERS, 2024 363 FIGURE 47 NUCLEAR MEDICINE SOFTWARE MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024 364 FIGURE 48 NUCLEAR MEDICINE SOFTWARE MARKET: COMPANY FOOTPRINT 365 FIGURE 49 NUCLEAR MEDICINE SOFTWARE MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 374 FIGURE 50 GE HEALTHCARE: COMPANY SNAPSHOT (2024) 382 FIGURE 51 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2024) 390 FIGURE 52 KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT (2024) 396 FIGURE 53 LANTHEUS: COMPANY SNAPSHOT (2024) 400 FIGURE 54 CANON MEDICAL SYSTEMS CORPORATION: COMPANY SNAPSHOT (2024) 405 FIGURE 55 MIRION TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2024) 409 FIGURE 56 RAYSEARCH LABORATORIES: COMPANY SNAPSHOT (2024) 438 FIGURE 57 SECTRA AB: COMPANY SNAPSHOT (2024) 443 FIGURE 58 AGFA-GEVAERT GROUP: COMPANY SNAPSHOT (2024) 446

同分類最新報告（醫療與生命科學）

查看醫療與生命科學全部報告 →

量子訊息有限公司為 MarketsandMarkets 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們